US6190640B1
(en)
*
|
1985-04-19 |
2001-02-20 |
Ludwig Institute For Cancer Research |
Method for treating neoplasia using humanized antibodies which bind to antigen A33
|
PT752248E
(pt)
*
|
1992-11-13 |
2001-01-31 |
Idec Pharma Corp |
Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
|
US5736137A
(en)
*
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
US7744877B2
(en)
|
1992-11-13 |
2010-06-29 |
Biogen Idec Inc. |
Expression and use of anti-CD20 Antibodies
|
US5595721A
(en)
*
|
1993-09-16 |
1997-01-21 |
Coulter Pharmaceutical, Inc. |
Radioimmunotherapy of lymphoma using anti-CD20
|
FR2724182B1
(fr)
*
|
1994-09-02 |
1996-12-13 |
Pasteur Institut |
Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations
|
US20030180290A1
(en)
*
|
1995-06-07 |
2003-09-25 |
Idec Pharmaceuticals Corporation |
Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
|
EP0885299B1
(en)
|
1996-01-08 |
2005-10-26 |
Genentech, Inc. |
Ob receptor and ligands
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
US6306393B1
(en)
*
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
US6183744B1
(en)
*
|
1997-03-24 |
2001-02-06 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
JP3957765B2
(ja)
|
1997-04-07 |
2007-08-15 |
ジェネンテク・インコーポレイテッド |
抗vegf抗体
|
ES2361267T3
(es)
|
1997-04-07 |
2011-06-15 |
Genentech Inc. |
Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria.
|
US6991790B1
(en)
|
1997-06-13 |
2006-01-31 |
Genentech, Inc. |
Antibody formulation
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
US6610293B1
(en)
|
1997-06-16 |
2003-08-26 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
DE69837897T2
(de)
|
1997-11-21 |
2008-03-06 |
Genentech Inc., San Francisco |
Mit A33 verwandte Antigene und deren pharmazeutische Verwendungen
|
EP1947119A3
(en)
|
1997-12-12 |
2012-12-19 |
Genentech, Inc. |
Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
|
ES2389387T3
(es)
|
1998-03-17 |
2012-10-25 |
Genentech, Inc. |
Polipéptidos homólogos de VEGF y de BMP1
|
EP2261229A3
(en)
|
1998-04-20 |
2011-03-23 |
GlycArt Biotechnology AG |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
EP3112468A1
(en)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17 homologous polypeptides and therapeutic uses thereof
|
DE69936382T3
(de)
|
1998-05-15 |
2011-07-07 |
Genentech, Inc., Calif. |
Therapeutische verwendungen von il-17 homologe polypeptide
|
EP1865061A3
(en)
|
1998-05-15 |
2007-12-19 |
Genentech, Inc. |
IL-17 homologous polypeptides and therapeutic uses thereof
|
AU4561199A
(en)
|
1998-06-12 |
1999-12-30 |
Genentech Inc. |
Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
|
US7250494B2
(en)
*
|
1998-06-15 |
2007-07-31 |
Biosynexus Incorporated |
Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
BR9913645A
(pt)
|
1998-08-11 |
2001-09-25 |
Idec Pharma Corp |
Terapias combinadas para linfomas de células b compreendendo a administração de anticorpo anti-cd20
|
US20010033839A1
(en)
*
|
1999-10-04 |
2001-10-25 |
Emilio Barbera-Guillem |
Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
|
US6224866B1
(en)
|
1998-10-07 |
2001-05-01 |
Biocrystal Ltd. |
Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
|
US6410319B1
(en)
|
1998-10-20 |
2002-06-25 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
AU761844C
(en)
|
1998-11-09 |
2004-09-23 |
F. Hoffmann-La Roche Ag |
Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
|
TWI253934B
(en)
*
|
1998-11-09 |
2006-05-01 |
Idec Pharma Corp |
Use of chimeric anti-CD20 antibody as in vitro or in vivo purging agent in patients receiving BMT or PBSC transplant
|
EP1950300A3
(en)
|
1998-11-18 |
2011-03-23 |
Genentech, Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
EP2075335A3
(en)
|
1998-12-22 |
2009-09-30 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
NZ539776A
(en)
*
|
1999-01-15 |
2006-12-22 |
Genentech Inc |
Polypeptide variants with altered effector function
|
US20020102208A1
(en)
|
1999-03-01 |
2002-08-01 |
Paul Chinn |
Radiolabeling kit and binding assay
|
MY133346A
(en)
*
|
1999-03-01 |
2007-11-30 |
Biogen Inc |
Kit for radiolabeling ligands with yttrium-90
|
US6207858B1
(en)
*
|
1999-03-03 |
2001-03-27 |
Idec Pharmaceuticals Corporation |
Regioselective synthesis of DTPA derivatives
|
EP1637160A3
(en)
|
1999-05-07 |
2006-05-03 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
|
US7829064B2
(en)
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
US8119101B2
(en)
*
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
US8383081B2
(en)
*
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
PT1194167E
(pt)
*
|
1999-06-09 |
2009-10-23 |
Immunomedics Inc |
Imunoterapia de doenças auto-imunitárias utilizando anticorpos que têm como alvo células b
|
DE60043322D1
(de)
|
1999-06-15 |
2009-12-24 |
Genentech Inc |
Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
|
CN100340575C
(zh)
|
1999-06-25 |
2007-10-03 |
杰南技术公司 |
人源化抗ErbB2抗体及其在制备药物中的应用
|
CN101264324A
(zh)
*
|
1999-07-12 |
2008-09-17 |
杰南技术公司 |
应用结合cd20的拮抗剂阻断对外来抗原的免疫应答
|
EP2264070A1
(en)
*
|
1999-08-11 |
2010-12-22 |
Biogen-Idec Inc. |
Treatment of intermediate-and high-grade non-hodgkins lymphoma with anti-CD20 antibody
|
EP1918305A1
(en)
*
|
1999-08-11 |
2008-05-07 |
Biogen Idec Inc. |
New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy
|
WO2001010462A1
(en)
*
|
1999-08-11 |
2001-02-15 |
Idec Pharmaceuticals Corporation |
Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
|
AU2005211669C1
(en)
*
|
1999-08-11 |
2017-09-21 |
F. Hoffmann-La Roche Ag |
Treatment of intermediate- and high-grade non-Hodgkins lymphoma with anti-CD20 antibody
|
US6451284B1
(en)
*
|
1999-08-11 |
2002-09-17 |
Idec Pharmaceuticals Corporation |
Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
DE60042693D1
(de)
|
1999-08-27 |
2009-09-17 |
Genentech Inc |
Dosierung für die behandlung mit anti erbb2-antikörpern
|
US20020028178A1
(en)
*
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
CA2491610A1
(en)
|
1999-12-01 |
2001-06-07 |
Kevin P. Baker |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
DK1897944T3
(da)
|
1999-12-23 |
2011-10-24 |
Genentech Inc |
IL-17 homologe polypeptider og terapeutisk anvendelse deraf
|
DE60137829D1
(de)
|
2000-01-13 |
2009-04-16 |
Genentech Inc |
Menschliche stra6 polypeptide
|
ES2267593T3
(es)
*
|
2000-02-16 |
2007-03-16 |
Genentech, Inc. |
Anticuerpos anti-april y celulas hibridomas.
|
US20030185796A1
(en)
*
|
2000-03-24 |
2003-10-02 |
Chiron Corporation |
Methods of therapy for non-hodgkin's lymphoma
|
ES2637801T3
(es)
|
2000-04-11 |
2017-10-17 |
Genentech, Inc. |
Anticuerpos multivalentes y usos de los mismos
|
CA2405632A1
(en)
*
|
2000-04-25 |
2001-11-01 |
Idec Pharmaceutical Corporation |
Intrathecal administration of rituximab for treatment of central nervous system lymphomas
|
AU6531101A
(en)
|
2000-06-02 |
2001-12-17 |
Genentech Inc |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
WO2001097858A2
(en)
|
2000-06-20 |
2001-12-27 |
Idec Pharmaceuticals Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
AU6541801A
(en)
*
|
2000-06-22 |
2002-01-02 |
Idec Pharma Corp |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
EP2275549A1
(en)
|
2000-06-23 |
2011-01-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
CA2648046A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
CN1446104A
(zh)
*
|
2000-07-12 |
2003-10-01 |
Idec药物公司 |
利用b细胞排除抗体和免疫调制抗体联合治疗b细胞恶性肿瘤的相关应用
|
EP1303293B1
(en)
|
2000-07-27 |
2008-12-03 |
Genentech, Inc. |
Sequential administration of cpt-11 and apo-2l polypeptide
|
ATE412009T1
(de)
|
2000-08-24 |
2008-11-15 |
Genentech Inc |
Methode zur inhibierung von il-22 induziertem pap1
|
EP1944317A3
(en)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
CN1592645A
(zh)
*
|
2000-09-18 |
2005-03-09 |
拜奥根Idec公司 |
使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
|
WO2002034790A1
(en)
*
|
2000-10-20 |
2002-05-02 |
Idec Pharmaceuticals Corporation |
Variant igg3 rituxan r and therapeutic use thereof
|
EP1334188B1
(en)
|
2000-11-07 |
2006-08-30 |
City of Hope |
Cd19-specific redirected immune cells
|
US7408041B2
(en)
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US7132510B2
(en)
|
2000-12-29 |
2006-11-07 |
Bio-Technology General (Israel) Ltd. |
Specific human antibodies for selective cancer therapy
|
US20040001822A1
(en)
*
|
2000-12-29 |
2004-01-01 |
Avigdor Levanon |
Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
|
US20040001839A1
(en)
*
|
2000-12-29 |
2004-01-01 |
Avigdor Levanon |
Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
|
US20040002450A1
(en)
*
|
2000-12-29 |
2004-01-01 |
Janette Lazarovits |
Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
|
US20030133939A1
(en)
*
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
RU2420537C2
(ru)
*
|
2001-01-17 |
2011-06-10 |
Трабьон Фармасьютикалз Инк. |
Слитые белки связывающий домен-иммуноглобулин
|
CA2436092A1
(en)
*
|
2001-01-29 |
2002-08-08 |
Idec Pharmaceutical Corporation |
Modified antibodies and methods of use
|
AU2007234621B2
(en)
*
|
2001-01-31 |
2010-08-26 |
Biogen Idec Inc. |
Use of immunoregulatory antibodies in the treatment of neoplastic disorders
|
US20020159996A1
(en)
*
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20070065436A1
(en)
*
|
2001-01-31 |
2007-03-22 |
Biogen Idec Inc. |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
EP2067486A1
(en)
|
2001-01-31 |
2009-06-10 |
Biogen Idec Inc. |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
US20030211107A1
(en)
*
|
2002-01-31 |
2003-11-13 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
CN100574803C
(zh)
|
2001-01-31 |
2009-12-30 |
拜奥根Idec公司 |
免疫调节抗体在治疗肿瘤性疾病中的用途
|
EP1366455B1
(en)
|
2001-02-19 |
2008-07-02 |
MERCK PATENT GmbH |
Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity
|
JP2005500018A
(ja)
*
|
2001-04-02 |
2005-01-06 |
アイデック ファーマスーティカルズ コーポレイション |
GnTIIIと同時発現する組換え抗体
|
ES2364816T3
(es)
*
|
2001-04-02 |
2011-09-14 |
Genentech, Inc. |
Terapia de combinación.
|
US20020193569A1
(en)
*
|
2001-06-04 |
2002-12-19 |
Idec Pharmaceuticals Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
KR100788092B1
(ko)
|
2001-06-20 |
2007-12-21 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
CN1555411A
(zh)
|
2001-08-03 |
2004-12-15 |
���迨�����\���ɷݹ�˾ |
抗体-依赖性细胞毒性增大的抗体糖基化变体
|
MXPA04001050A
(es)
*
|
2001-08-03 |
2004-07-08 |
Genentech Inc |
Polipeptidos tacis y br3 y usos de los mismos.
|
US6658260B2
(en)
|
2001-09-05 |
2003-12-02 |
Telecommunication Systems, Inc. |
Inter-carrier short messaging service providing phone number only experience
|
DE60238143D1
(de)
|
2001-09-18 |
2010-12-09 |
Genentech Inc |
Zusammensetzungen und verfahren für die diagnose von tumoren
|
ATE443259T1
(de)
|
2001-09-20 |
2009-10-15 |
Univ Texas |
Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
|
US20030157641A1
(en)
*
|
2001-11-16 |
2003-08-21 |
Idec Pharmaceuticals Corporation |
Polycistronic expression of antibodies
|
JP2005535282A
(ja)
*
|
2001-11-16 |
2005-11-24 |
アイデック ファーマシューティカルズ コーポレイション |
抗体のポリシストロニック発現
|
AR037756A1
(es)
|
2001-12-17 |
2004-12-01 |
Bayer Corp |
Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
|
US20040052779A1
(en)
*
|
2001-12-21 |
2004-03-18 |
Stinson Jeffrey R. |
Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
|
MXPA04006554A
(es)
|
2002-01-02 |
2005-03-31 |
Genentech Inc |
Composiciones y metodos para diagnostico y tratamiento de tumor.
|
CN102659945B
(zh)
|
2002-01-25 |
2016-12-21 |
诺沃挪第克公司 |
抗C5aR抗体及其应用
|
JP4460302B2
(ja)
|
2002-02-05 |
2010-05-12 |
ジェネンテック インコーポレイテッド |
タンパク質精製法
|
JP4498746B2
(ja)
*
|
2002-02-14 |
2010-07-07 |
イミューノメディクス、インコーポレイテッド |
抗cd20抗体およびその融合タンパク質ならびに使用法
|
US8287864B2
(en)
|
2002-02-14 |
2012-10-16 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
JP2005526501A
(ja)
|
2002-02-21 |
2005-09-08 |
デューク・ユニヴァーシティ |
自己免疫疾患用の試薬および治療方法
|
JP2005535290A
(ja)
|
2002-02-22 |
2005-11-24 |
ジェネンテック・インコーポレーテッド |
免疫関連疾患の治療のための組成物と方法
|
SI1485477T1
(sl)
|
2002-02-25 |
2009-10-31 |
Genentech Inc |
Novi citokinski receptor GLM-R tipa 1
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
ATE477276T1
(de)
*
|
2002-03-01 |
2010-08-15 |
Immunomedics Inc |
Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
BRPI0308585B8
(pt)
|
2002-03-13 |
2021-05-25 |
Biogen Idec Inc |
anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna
|
US20030180292A1
(en)
*
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
ES2401428T3
(es)
|
2002-04-10 |
2013-04-19 |
Genentech, Inc. |
Variantes de anticuerpos anti-HER2
|
EP2011886A3
(en)
|
2002-04-16 |
2009-02-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US20040202665A1
(en)
*
|
2002-07-01 |
2004-10-14 |
Janette Lazarovits |
Compositions and methods for therapeutic treatment
|
US20040208877A1
(en)
*
|
2002-07-01 |
2004-10-21 |
Avigdor Levanon |
Antibodies and uses thereof
|
WO2004004649A2
(en)
|
2002-07-08 |
2004-01-15 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
AU2003248921A1
(en)
*
|
2002-07-09 |
2004-01-23 |
Point Therapeutics, Inc. |
Boroproline compound combination therapy
|
RU2338751C2
(ru)
|
2002-07-15 |
2008-11-20 |
Дженентек, Инк. |
СПОСОБЫ ИДЕНТИФИКАЦИИ ОПУХОЛЕЙ, ВОСПРИИМЧИВЫХ К ЛЕЧЕНИЮ АНТИТЕЛАМИ ПРОТИВ ErbB2
|
CA2492447A1
(en)
*
|
2002-07-25 |
2004-02-05 |
Genentech, Inc. |
Taci antibodies and uses thereof
|
US20040171809A1
(en)
|
2002-09-09 |
2004-09-02 |
Korsmeyer Stanley J. |
BH3 peptides and method of use thereof
|
WO2004024068A2
(en)
|
2002-09-11 |
2004-03-25 |
Genentech, Inc. |
Novel composition and methods for the treatment of immune related diseases
|
WO2004024072A2
(en)
|
2002-09-11 |
2004-03-25 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
JP2006515165A
(ja)
|
2002-09-16 |
2006-05-25 |
ジェネンテック・インコーポレーテッド |
免疫関連疾患の治療のための新規組成物と方法
|
WO2004028479A2
(en)
|
2002-09-25 |
2004-04-08 |
Genentech, Inc. |
Nouvelles compositions et methodes de traitement du psoriasis
|
ES2562177T3
(es)
|
2002-09-27 |
2016-03-02 |
Xencor Inc. |
Variantes de Fc optimizadas y métodos para su generación
|
KR100944575B1
(ko)
*
|
2002-10-17 |
2010-02-25 |
젠맵 에이/에스 |
Cd20에 대한 인간 모노클로날 항체
|
JP2006517785A
(ja)
|
2002-10-29 |
2006-08-03 |
ジェネンテック・インコーポレーテッド |
免疫関連疾患の治療のための新規組成物と方法
|
AU2003295401B2
(en)
|
2002-11-08 |
2010-04-29 |
Genentech, Inc. |
Compositions and methods for the treatment of natural killer cell related diseases
|
WO2004047728A2
(en)
|
2002-11-26 |
2004-06-10 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
EP1944320A1
(en)
*
|
2002-12-16 |
2008-07-16 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
US7534427B2
(en)
*
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
ATE475708T1
(de)
|
2003-01-22 |
2010-08-15 |
Glycart Biotechnology Ag |
Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion
|
PL379264A1
(pl)
*
|
2003-01-27 |
2006-08-07 |
Biogen Idec Ma Inc. |
Kompozycje i sposoby leczenia raka przy zastosowaniu IGSF9 i LIV-1
|
AU2004209638B2
(en)
|
2003-02-01 |
2011-02-03 |
Tanox, Inc. |
High affinity anti-human IgE antibodies
|
GB0304576D0
(en)
*
|
2003-02-28 |
2003-04-02 |
Lonza Biologics Plc |
Protein a chromatography
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
JP4869064B2
(ja)
|
2003-04-04 |
2012-02-01 |
ジェネンテック, インコーポレイテッド |
高濃度抗体及びタンパク質製剤
|
NZ587776A
(en)
*
|
2003-04-09 |
2012-03-30 |
Genentech Inc |
Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor using anti-CD20 antibody
|
WO2004101756A2
(en)
|
2003-05-09 |
2004-11-25 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
EP1626993B1
(en)
|
2003-05-09 |
2015-03-11 |
Duke University |
Cd20-specific antibodies and methods of employing same
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
JP4745242B2
(ja)
*
|
2003-05-20 |
2011-08-10 |
アプライド モレキュラー エボリューション,インコーポレイテッド |
Cd20結合分子
|
RS20181002A1
(sr)
|
2003-05-30 |
2018-12-31 |
Genentech Inc |
Tretman sa anti-vegf antitelima
|
BRPI0411276A
(pt)
*
|
2003-06-05 |
2006-08-01 |
Genentech Inc |
métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
DK1636593T5
(da)
|
2003-06-06 |
2009-07-27 |
Genentech Inc |
Modulering af vekselvirkningen mellem HGF-beta-kæde og c-met
|
US20050232931A1
(en)
*
|
2003-06-13 |
2005-10-20 |
Oncomax Acquisition Corp. |
Preparation and application of anti-tumor bifunctional fusion proteins
|
US20040254108A1
(en)
*
|
2003-06-13 |
2004-12-16 |
Jing Ma |
Preparation and application of anti-tumor bifunctional fusion proteins
|
US20050266009A1
(en)
*
|
2003-06-30 |
2005-12-01 |
Savient Pharmaceuticals, Inc. |
Antibodies and uses thereof
|
US20050069955A1
(en)
*
|
2003-06-30 |
2005-03-31 |
Daniel Plaksin |
Antibodies and uses thereof
|
US20050152906A1
(en)
*
|
2003-06-30 |
2005-07-14 |
Avigdor Levanon |
Specific human antibodies
|
US20050100543A1
(en)
|
2003-07-01 |
2005-05-12 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
KR100945327B1
(ko)
|
2003-07-08 |
2010-03-08 |
제넨테크, 인크. |
Il-17a/f 이종 폴리펩티드 및 그의 치료 용도
|
US7579157B2
(en)
|
2003-07-10 |
2009-08-25 |
Hoffmann-La Roche Inc. |
Antibody selection method against IGF-IR
|
US7834155B2
(en)
*
|
2003-07-21 |
2010-11-16 |
Immunogen Inc. |
CA6 antigen-specific cytotoxic conjugate and methods of using the same
|
DK1660513T5
(da)
*
|
2003-07-21 |
2011-07-18 |
Immunogen Inc |
CA6 antigen-specifikt, cytotoksisk konjugat og fremgangsmåder til anvendelse heraf
|
WO2005012256A1
(en)
|
2003-07-22 |
2005-02-10 |
Astex Therapeutics Limited |
3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
US20050032130A1
(en)
*
|
2003-07-29 |
2005-02-10 |
Genentech, Inc. |
Neutralizing antibody assay and uses therefor
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US8147832B2
(en)
*
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
WO2005023302A2
(en)
*
|
2003-08-29 |
2005-03-17 |
Genentech, Inc. |
Anti-cd20 therapy of ocular disorders
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
ATE516819T1
(de)
|
2003-11-04 |
2011-08-15 |
Novartis Vaccines & Diagnostic |
Verfahren zur behandlung von b-zell-bedingtem krebs
|
PL1692182T3
(pl)
|
2003-11-05 |
2010-09-30 |
Roche Glycart Ag |
Przeciwciała CD20 o zwiększonym powinowactwie wiązania z receptorem Fc oraz zwiększonej funkcji efektorowej
|
CA2542886A1
(en)
|
2003-11-05 |
2005-05-19 |
Neelima M. Bhat |
Enhanced b cell cytotoxicity of cdim binding antibody
|
JP2008504002A
(ja)
|
2003-11-12 |
2008-02-14 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
新生児Fcレセプター(FcRn)結合ポリペプチド改変体、ダイマーFc結合タンパク質、およびそれらに関連する方法
|
EP2412725A3
(en)
|
2003-11-17 |
2012-04-25 |
Genentech, Inc. |
Antibodies against CD79b for the treatment of tumor of hematopoeitic origin
|
US7750123B2
(en)
|
2003-11-25 |
2010-07-06 |
Dana Farber Cancer Institute, Inc. |
Antibodies against SARS-CoV and methods of use thereof
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
US20050233960A1
(en)
|
2003-12-11 |
2005-10-20 |
Genentech, Inc. |
Methods and compositions for inhibiting c-met dimerization and activation
|
US20050186206A1
(en)
*
|
2003-12-19 |
2005-08-25 |
Genentech, Inc. |
Detection of CD20 in therapy of autoimmune diseases
|
AU2004303848A1
(en)
*
|
2003-12-19 |
2005-07-07 |
Genentech, Inc. |
Detection of CD20 in transplant rejection
|
EP2275448A3
(en)
|
2003-12-19 |
2013-02-06 |
Genentech, Inc. |
Monovalent antibody fragments useful as therapeutics
|
EP3476861A1
(en)
|
2004-01-07 |
2019-05-01 |
Novartis Vaccines and Diagnostics, Inc. |
M-csf-specific monoclonal antibody and uses thereof
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
AU2005214382B2
(en)
|
2004-02-19 |
2011-08-04 |
Genentech, Inc. |
CDR-repaired antibodies
|
CA2560759A1
(en)
|
2004-03-03 |
2005-12-22 |
Iq Corporation |
Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof
|
DK1737891T3
(da)
|
2004-04-13 |
2013-03-25 |
Hoffmann La Roche |
Anti-p-selectin-antistoffer
|
WO2005115453A2
(en)
*
|
2004-04-16 |
2005-12-08 |
Genentech, Inc. |
Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
|
EP1735000A2
(en)
*
|
2004-04-16 |
2006-12-27 |
Genentech, Inc. |
Method for augmenting b cell depletion
|
US7850962B2
(en)
|
2004-04-20 |
2010-12-14 |
Genmab A/S |
Human monoclonal antibodies against CD20
|
ZA200608982B
(en)
*
|
2004-05-05 |
2008-06-25 |
Genentech Inc |
Preventing autoimmune disease by using an anti-CD20 antibody
|
US20060024295A1
(en)
*
|
2004-06-04 |
2006-02-02 |
Genentech, Inc. |
Method for treating lupus
|
NZ604082A
(en)
*
|
2004-06-04 |
2014-09-26 |
Genentech Inc |
Method for treating multiple sclerosis
|
SV2006002143A
(es)
|
2004-06-16 |
2006-01-26 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento del cancer resistente al platino
|
EP1778718B1
(en)
|
2004-07-02 |
2014-10-08 |
Genentech, Inc. |
Inhibitors of iap
|
JP2008505148A
(ja)
*
|
2004-07-09 |
2008-02-21 |
バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト |
B細胞リンパ腫の治療における放射線標識化抗cd20抗体を使用する組合わせ治療
|
EP2471813B1
(en)
|
2004-07-15 |
2014-12-31 |
Xencor, Inc. |
Optimized Fc variants
|
AU2005269716B2
(en)
|
2004-07-20 |
2011-01-27 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
ES2521140T3
(es)
|
2004-07-22 |
2014-11-12 |
Genentech, Inc. |
Composición de anticuerpos de HER2
|
EP1781378A2
(en)
*
|
2004-07-22 |
2007-05-09 |
Genentech, Inc. |
Method of treating sjögren's syndrome
|
CA2570323C
(en)
|
2004-07-26 |
2014-08-26 |
Genentech, Inc. |
Methods and compositions for modulating hepatocyte growth factor activation
|
US20070286855A1
(en)
*
|
2004-08-03 |
2007-12-13 |
Mayo Foundation For Medical Education And Research |
Improving treatments
|
ES2426817T3
(es)
|
2004-08-04 |
2013-10-25 |
Mentrik Biotech, Llc |
Regiones Fc variantes
|
RU2453558C2
(ru)
|
2004-09-03 |
2012-06-20 |
Дженентек, Инк. |
Гуманизированные антагонистические антитела против бета7 и их применение
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
CN101065151B
(zh)
|
2004-09-23 |
2014-12-10 |
健泰科生物技术公司 |
半胱氨酸改造的抗体和偶联物
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
WO2006038212A2
(en)
*
|
2004-10-04 |
2006-04-13 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Methods and compositions for the diagnosis and treatment of cancer
|
EP1812060A2
(en)
*
|
2004-10-05 |
2007-08-01 |
Genentech, Inc. |
Method for treating vasculitis
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
EP1814544A4
(en)
*
|
2004-11-05 |
2009-12-02 |
Cephalon Inc |
CANCER TREATMENTS
|
EP2325207B1
(en)
|
2004-11-12 |
2017-03-15 |
Xencor, Inc. |
FC variants with altered binding to FCRN
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
FR2879204B1
(fr)
*
|
2004-12-15 |
2007-02-16 |
Lab Francais Du Fractionnement |
Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
|
ES2349110T5
(es)
|
2004-12-20 |
2013-11-27 |
Genentech, Inc. |
Inhibidores de IAP derivados de pirrolidina
|
EP1674457B1
(en)
|
2004-12-23 |
2009-06-03 |
GPC Biotech AG |
Derivatives of squaric acid with anti-proliferative activity
|
JP2008526234A
(ja)
|
2005-01-05 |
2008-07-24 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Cripto結合分子
|
JP2008526883A
(ja)
|
2005-01-07 |
2008-07-24 |
ディアデクサス インコーポレーテッド |
Ovr110抗体組成物および使用方法
|
CN101102793A
(zh)
*
|
2005-01-13 |
2008-01-09 |
健泰科生物技术公司 |
治疗方法
|
US8436190B2
(en)
|
2005-01-14 |
2013-05-07 |
Cephalon, Inc. |
Bendamustine pharmaceutical compositions
|
CN101141981A
(zh)
|
2005-01-21 |
2008-03-12 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
BRPI0606455A
(pt)
|
2005-01-21 |
2008-03-11 |
Astex Therapeutics Ltd |
compostos farmacêuticos
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
DOP2006000029A
(es)
*
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
KR20070108402A
(ko)
*
|
2005-02-15 |
2007-11-09 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
화학요법제와 il-2 및 선택적으로 항-cd20 항체의조합물을 사용하여 임파종을 치료하는 방법
|
US8329178B2
(en)
|
2005-02-18 |
2012-12-11 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against CXCR4 and methods of use thereof
|
DK1850874T3
(da)
|
2005-02-23 |
2013-11-11 |
Genentech Inc |
Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
EP1870456A4
(en)
*
|
2005-03-31 |
2008-08-27 |
Univ Osaka |
PROCESS FOR PREPARING AN ANTIBODY TESTED AGAINST A CELL MEMBRANE SURFACE ANTIGENEPITOPE AND TEST METHODS
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
US20090214536A1
(en)
|
2005-04-07 |
2009-08-27 |
Guoying Yu |
CACNA1E in Cancer Diagnosis, Detection and Treatment
|
EP1871911A2
(en)
|
2005-04-07 |
2008-01-02 |
Chiron Corporation |
Cancer-related genes (prlr)
|
AR053579A1
(es)
*
|
2005-04-15 |
2007-05-09 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria intestinal (eii)
|
BRPI0612972A2
(pt)
*
|
2005-04-22 |
2010-12-14 |
Genentech Inc |
mÉtodo para tratar doenÇa de alzheimer, mÉtodo para tratar demÊncia, artigo de fabricaÇço e usos de um anticorpo cd20
|
JP2008539731A
(ja)
*
|
2005-05-02 |
2008-11-20 |
コールド スプリング ハーバー ラボラトリー |
癌の診断及び治療のための組成物及び方法
|
US7430425B2
(en)
*
|
2005-05-17 |
2008-09-30 |
Telecommunication Systems, Inc. |
Inter-carrier digital message with user data payload service providing phone number only experience
|
US8124084B2
(en)
|
2005-05-17 |
2012-02-28 |
University Of Connecticut |
Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra
|
KR20080046135A
(ko)
*
|
2005-05-20 |
2008-05-26 |
제넨테크, 인크. |
자가면역 질환 대상체로부터의 생물학적 샘플의 예비처리
|
US20090285795A1
(en)
|
2005-05-24 |
2009-11-19 |
Villoo Morawala Patell |
Method for the Production of a Monoclonal Antibody to CD20 for the Treatment of B-Cell Lymphoma
|
GB0510790D0
(en)
|
2005-05-26 |
2005-06-29 |
Syngenta Crop Protection Ag |
Anti-CD16 binding molecules
|
JP2008541781A
(ja)
|
2005-06-06 |
2008-11-27 |
ジェネンテック・インコーポレーテッド |
異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用
|
WO2007094842A2
(en)
|
2005-12-02 |
2007-08-23 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
CN102875681A
(zh)
|
2005-07-08 |
2013-01-16 |
拜奥根Idec马萨诸塞公司 |
抗-αvβ6抗体及其用途
|
ES2530265T3
(es)
|
2005-07-21 |
2015-02-27 |
Genmab A/S |
Ensayos de potencia de unión de una sustancia medicamentosa de anticuerpo a un receptor FC
|
US20080279850A1
(en)
*
|
2005-07-25 |
2008-11-13 |
Trubion Pharmaceuticals, Inc. |
B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
|
CN101267836A
(zh)
|
2005-07-25 |
2008-09-17 |
特鲁比昂药品公司 |
单剂量cd20特异性结合分子的用途
|
SI2298815T1
(sl)
*
|
2005-07-25 |
2015-08-31 |
Emergent Product Development Seattle, Llc |
Zmanjšanje števila celic b z uporabo molekul, ki se specifično vežejo na cd37 in cd20
|
WO2007016285A2
(en)
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
M-csf specific monoclonal antibody and uses thereof
|
JP2009504183A
(ja)
|
2005-08-15 |
2009-02-05 |
ジェネンテック・インコーポレーテッド |
遺伝子破壊、それに関連する組成物および方法
|
EP1762575A1
(en)
*
|
2005-09-12 |
2007-03-14 |
Ganymed Pharmaceuticals AG |
Identification of tumor-associated antigens for diagnosis and therapy
|
DK1931709T3
(en)
|
2005-10-03 |
2017-03-13 |
Xencor Inc |
FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
|
WO2007056441A2
(en)
|
2005-11-07 |
2007-05-18 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
CN101360826B
(zh)
|
2005-11-18 |
2014-04-30 |
格兰马克药品股份有限公司 |
抗α2整联蛋白抗体及它们的用途
|
CA2630432A1
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
JP6088723B2
(ja)
*
|
2005-11-23 |
2017-03-01 |
ジェネンテック, インコーポレイテッド |
B細胞アッセイに関する組成物及び方法。
|
WO2007064911A1
(en)
*
|
2005-12-02 |
2007-06-07 |
Biogen Idec Inc. |
Anti-mouse cd20 antibodies and uses thereof
|
EP1979379B1
(en)
|
2005-12-02 |
2013-09-18 |
Dana-Farber Cancer Institute |
Carbonic anhydrase ix (g250) antibodies and methods of use thereof
|
KR101453570B1
(ko)
|
2005-12-02 |
2014-10-22 |
제넨테크, 인크. |
Il-22 및 il-22r에 결합하는 항체를 포함하는,사이토카인 신호 전달과 관련된 질환 및 장애 치료용조성물 및 치료 방법
|
ES2535856T3
(es)
|
2005-12-15 |
2015-05-18 |
Genentech, Inc. |
Métodos y composiciones para dirigirse a la poliubiquitina
|
RU2451025C2
(ru)
|
2005-12-19 |
2012-05-20 |
Дженентек, Инк. |
Ингибиторы iap
|
US8101365B2
(en)
|
2006-01-05 |
2012-01-24 |
Genentech, Inc. |
Anti-EphB4 antibodies and methods using same
|
WO2007127506A2
(en)
|
2006-01-20 |
2007-11-08 |
Genentech, Inc. |
Anti-ephrinb2 antibodies and methods using same
|
DE602007011206D1
(de)
|
2006-02-06 |
2011-01-27 |
Rhode Island Hospital Providence |
Gpr30-östrogenrezeptor bei mammakarzinomen
|
WO2007114979A2
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
US7829086B2
(en)
|
2006-03-06 |
2010-11-09 |
Medimmune, Llc |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
US8389688B2
(en)
|
2006-03-06 |
2013-03-05 |
Aeres Biomedical, Ltd. |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
JPWO2007102200A1
(ja)
|
2006-03-07 |
2009-07-23 |
国立大学法人大阪大学 |
抗cd20モノクローナル抗体
|
EP2946786A1
(en)
|
2006-03-08 |
2015-11-25 |
Wake Forest University Health Sciences |
Soluble monomeric Ephrin A1
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
WO2007111661A2
(en)
|
2006-03-20 |
2007-10-04 |
Xoma Technology Ltd. |
Human antibodies specific for gastrin materials and methods
|
CA2646597A1
(en)
|
2006-03-21 |
2007-09-27 |
The Regents Of The University Of California |
N-cadherin and ly6 e: targets for cancer diagnosis and therapy
|
US20100278821A1
(en)
|
2006-03-21 |
2010-11-04 |
The Regents Of The University Of California |
N-cadherin: target for cancer diagnosis and therapy
|
PL1989231T3
(pl)
|
2006-03-21 |
2015-10-30 |
Genentech Inc |
Terapia kombinatoryczna z udziałem antagonistów alfa5beta1
|
EP2004221A2
(en)
|
2006-03-23 |
2008-12-24 |
Novartis Pharma AG |
Anti-tumor cell antigen antibody therapeutics
|
EP2008106A2
(en)
|
2006-03-31 |
2008-12-31 |
Dana-Farber Cancer Institute |
Methods of determining cellular chemosensitivity
|
AU2007243946B2
(en)
|
2006-04-05 |
2012-11-29 |
Curis, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
US7846724B2
(en)
|
2006-04-11 |
2010-12-07 |
Hoffmann-La Roche Inc. |
Method for selecting CHO cell for production of glycosylated antibodies
|
US20080014203A1
(en)
|
2006-04-11 |
2008-01-17 |
Silke Hansen |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
MX2008013121A
(es)
|
2006-04-13 |
2009-03-25 |
Novartis Vaccines & Diagnostic |
Metodo para tratar, diagnosticar o detectar cancer.
|
EP2011870A4
(en)
|
2006-04-14 |
2010-09-15 |
Medical & Biol Lab Co Ltd |
MUTANT POLYPEPTIDE WITH EFFECTOR FUNCTION
|
US20090288176A1
(en)
|
2006-04-19 |
2009-11-19 |
Genentech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
US7727525B2
(en)
|
2006-05-11 |
2010-06-01 |
City Of Hope |
Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
|
WO2007140371A2
(en)
|
2006-05-30 |
2007-12-06 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
NZ573646A
(en)
*
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
JP5829004B2
(ja)
|
2006-06-30 |
2015-12-09 |
ノボ・ノルデイスク・エー/エス |
抗nkg2a抗体とその使用
|
JP2009542810A
(ja)
|
2006-07-10 |
2009-12-03 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Smad4欠損癌の増殖を阻害するための組成物および方法
|
CN101511181B
(zh)
|
2006-07-11 |
2013-08-21 |
新泽西医科和牙科大学 |
蛋白、编码该蛋白的核酸和相关的应用方法
|
US20100098632A1
(en)
*
|
2006-07-12 |
2010-04-22 |
Russell Stephen J |
Hydroxyapatite particles
|
JP5406027B2
(ja)
|
2006-08-04 |
2014-02-05 |
ノバルティス アーゲー |
EphB3特異的抗体およびその使用
|
CA2660286A1
(en)
|
2006-08-09 |
2008-02-21 |
Homestead Clinical Corporation |
Organ-specific proteins and methods of their use
|
AR062435A1
(es)
|
2006-08-18 |
2008-11-05 |
Xoma Technology Ltd |
Anticuerpo especifico prlr (receptor de prolactina) y sus usos
|
EP2455404B1
(en)
|
2006-08-22 |
2016-02-10 |
Novo Nordisk A/S |
Anti-C5AR antibodies with improved properties
|
EP2061900A2
(en)
|
2006-08-25 |
2009-05-27 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
US20080058922A1
(en)
*
|
2006-08-31 |
2008-03-06 |
Cardiac Pacemakers, Inc. |
Methods and devices employing vap-1 inhibitors
|
US8372399B2
(en)
*
|
2006-08-31 |
2013-02-12 |
Cardiac Pacemakers, Inc. |
Bispecific antibodies and agents to enhance stem cell homing
|
US8636995B2
(en)
*
|
2006-08-31 |
2014-01-28 |
Cardiac Pacemakers, Inc. |
Methods and devices to regulate stem cell homing
|
ES2372217T3
(es)
|
2006-09-12 |
2012-01-17 |
Genentech, Inc. |
Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
|
US9505821B2
(en)
|
2006-10-03 |
2016-11-29 |
Rutgers, The State University Of New Jersey |
ATAP peptides, nucleic acids encoding the same and associated methods of use
|
US9382327B2
(en)
|
2006-10-10 |
2016-07-05 |
Vaccinex, Inc. |
Anti-CD20 antibodies and methods of use
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
US8883790B2
(en)
|
2006-10-12 |
2014-11-11 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
PT2845866T
(pt)
|
2006-10-27 |
2017-08-09 |
Genentech Inc |
Anticorpos e imunoconjugados e utilizações dos mesmos
|
MX2009004664A
(es)
|
2006-11-02 |
2009-10-12 |
Daniel J Capon |
Inmunoglobulinas hibridas con partes moviles.
|
EP3156415A1
(en)
|
2006-11-22 |
2017-04-19 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
|
WO2008067283A2
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
MX2009006034A
(es)
|
2006-12-07 |
2009-10-12 |
Novartis Ag |
Anticuerpos antagonistas contra ephb3.
|
WO2008079735A1
(en)
|
2006-12-19 |
2008-07-03 |
Genentech, Inc. |
Imidazopyridine inhibitors of iap
|
ATE516814T1
(de)
|
2007-02-02 |
2011-08-15 |
Bristol Myers Squibb Co |
10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
|
US7834154B2
(en)
|
2007-02-09 |
2010-11-16 |
Genentech, Inc. |
Anti-ROBO4 antibodies and uses therefor
|
KR101598229B1
(ko)
|
2007-02-16 |
2016-02-26 |
메리맥 파마슈티컬즈, 인크. |
Erbb3에 대한 항체 및 이의 용도
|
CA2676790A1
(en)
|
2007-02-22 |
2008-08-28 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
EP2132573B1
(en)
|
2007-03-02 |
2014-04-23 |
Genentech, Inc. |
Predicting response to a her dimerisation inhbitor based on low her3 expression
|
EP3202786A3
(en)
|
2007-03-12 |
2017-10-11 |
ESBATech, an Alcon Biomedical Research Unit LLC |
Sequence based engineering and optimization of single chain antibodies
|
WO2008112988A2
(en)
|
2007-03-14 |
2008-09-18 |
Novartis Ag |
Apcdd1 inhibitors for treating, diagnosing or detecting cancer
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
EP2644205B1
(en)
|
2007-04-12 |
2018-06-13 |
The Brigham and Women's Hospital, Inc. |
Targeting ABCB5 for cancer therapy
|
FR2915398B1
(fr)
*
|
2007-04-25 |
2012-12-28 |
Lab Francais Du Fractionnement |
"ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
|
KR20100024923A
(ko)
|
2007-04-30 |
2010-03-08 |
제넨테크, 인크. |
Iap의 억제제
|
WO2009101479A2
(en)
|
2007-05-14 |
2009-08-20 |
Novimmune Sa |
Fc receptor-binding polypeptides with modified effector functions
|
EP2019101A1
(en)
*
|
2007-07-26 |
2009-01-28 |
GPC Biotech AG |
Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
KR101572700B1
(ko)
|
2007-06-07 |
2015-11-30 |
제넨테크, 인크. |
보체-관련 장애의 예방 및 치료를 위한 C3b 항체 및 방법
|
CA2689941C
(en)
|
2007-06-25 |
2019-10-29 |
Esbatech Ag |
Methods of modifying antibodies, and modified antibodies with improved functional properties
|
US9908945B2
(en)
*
|
2007-06-25 |
2018-03-06 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Sequence based engineering and optimization of single chain antibodies
|
DK3597659T3
(da)
|
2007-07-09 |
2023-04-03 |
Genentech Inc |
Forhindring af disulfidbindingsreduktion under rekombinant produktion af polypeptider
|
SG183023A1
(en)
|
2007-07-16 |
2012-08-30 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
EP2641618A3
(en)
|
2007-07-16 |
2013-10-23 |
Genentech, Inc. |
Humanized anti-CD79B antibodies and immunoconjugates and methods of use
|
MY147651A
(en)
*
|
2007-07-31 |
2012-12-31 |
Regeneron Pharma |
Human antibodies to human cd20 and method of using thereof
|
DK2185719T3
(en)
|
2007-08-02 |
2014-02-17 |
Novimmune Sa |
ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
JP2010536365A
(ja)
|
2007-08-24 |
2010-12-02 |
オンコセラピー・サイエンス株式会社 |
前立腺癌の治療及び診断の標的遺伝子のための、pkib及びnaaladl2
|
JP2010536844A
(ja)
|
2007-08-24 |
2010-12-02 |
オンコセラピー・サイエンス株式会社 |
癌の治療標的及び診断マーカーとしてのdkk1癌遺伝子
|
US20100226925A1
(en)
|
2007-09-14 |
2010-09-09 |
Amgen Inc. |
Homogeneous Antibody Populations
|
MX2010003450A
(es)
|
2007-09-26 |
2010-04-27 |
Chugai Pharmaceutical Co Ltd |
Region constante de anticuerpo modificada.
|
ES2565202T3
(es)
|
2007-10-16 |
2016-04-01 |
Zymogenetics, Inc. |
Combinación de activador transmembrana y modulador de calcio e interactor de ligando de ciclofilina (TACI) y agentes anti-CD20 para tratamiento de enfermedades autoinmunitarias
|
PL2565206T3
(pl)
*
|
2007-10-30 |
2017-08-31 |
Genentech, Inc. |
Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej
|
PT2514436T
(pt)
|
2007-11-07 |
2018-03-21 |
Genentech Inc |
Il-22 para utilização no tratamento de distúrbios microbianos
|
CA2704973A1
(en)
|
2007-11-08 |
2009-05-14 |
Genentech, Inc. |
Anti-factor b antibodies and their uses
|
DK2220116T3
(da)
|
2007-11-12 |
2012-11-26 |
Theraclone Sciences Inc |
Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
|
WO2010135521A2
(en)
|
2009-05-20 |
2010-11-25 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
CA2705923A1
(en)
|
2007-11-16 |
2009-05-22 |
Nuvelo, Inc. |
Antibodies to lrp6
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗-vegf抗體
|
EP3524619A1
(en)
|
2007-12-06 |
2019-08-14 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against influenza virus and methods of use thereof
|
HUE024903T2
(en)
|
2007-12-26 |
2016-02-29 |
Xencor Inc |
FC variants with modified binding to FCRN
|
US8962806B2
(en)
|
2007-12-28 |
2015-02-24 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
EP2077281A1
(en)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
US7914785B2
(en)
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
US9181327B2
(en)
|
2008-01-07 |
2015-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-HIV domain antibodies and method of making and using same
|
ATE548052T1
(de)
|
2008-01-17 |
2012-03-15 |
Philogen Spa |
Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
|
ES2414804T3
(es)
|
2008-01-18 |
2013-07-22 |
Genentech, Inc. |
Métodos y composiciones que se dirigen a la poliubiquitina
|
AR070141A1
(es)
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
EP2247619A1
(en)
|
2008-01-24 |
2010-11-10 |
Novo Nordisk A/S |
Humanized anti-human nkg2a monoclonal antibody
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
IL295449A
(en)
|
2008-01-31 |
2022-10-01 |
Genentech Inc |
and fusion antibody-drug-cd79b engineered antibodies cysteine-
|
JP2011515073A
(ja)
|
2008-02-20 |
2011-05-19 |
ジーツー インフラメイション プロプライエタリー リミテッド |
ヒト化抗C5aR抗体
|
WO2009111085A1
(en)
*
|
2008-03-07 |
2009-09-11 |
Biogen Idec Ma Inc. |
Use of cd23 antibodies to treat malignancies in patients with poor prognosis
|
AU2009223688B2
(en)
|
2008-03-10 |
2014-12-11 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
|
AR072777A1
(es)
|
2008-03-26 |
2010-09-22 |
Cephalon Inc |
Formas solidas de clorhidrato de bendamustina
|
HUE036780T2
(hu)
|
2008-04-09 |
2018-07-30 |
Genentech Inc |
Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
|
WO2009126944A1
(en)
|
2008-04-11 |
2009-10-15 |
Trubion Pharmaceuticals, Inc. |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
EP2112152A1
(en)
|
2008-04-22 |
2009-10-28 |
GPC Biotech AG |
Dihydropteridinones as Plk Inhibitors
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
EP2282769A4
(en)
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
JP2011520961A
(ja)
|
2008-05-22 |
2011-07-21 |
ブリストル−マイヤーズ スクイブ カンパニー |
多価フィブロネクチンをベースとする足場ドメインタンパク質
|
JP2011523853A
(ja)
|
2008-06-03 |
2011-08-25 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリン及びその使用
|
KR20110016959A
(ko)
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
BRPI0915374B1
(pt)
|
2008-06-10 |
2021-05-25 |
Abbvie Inc |
Composto n-((1s,3r,4s)-3-etil-4-(6h-pirrolo[2,3-e][1,2,4]triazolo[4,3-a]pirazin-1-il)ciclopentil) ciclopropanosulfonamida e um sal farmaceuticamente aceitável deste
|
EP3241843B1
(en)
|
2008-06-25 |
2021-07-28 |
Novartis AG |
Solubility optimization of immunobinders
|
SG192489A1
(en)
*
|
2008-07-08 |
2013-08-30 |
Abbott Lab |
Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
|
WO2010009271A2
(en)
|
2008-07-15 |
2010-01-21 |
Academia Sinica |
Glycan arrays on ptfe-like aluminum coated glass slides and related methods
|
JP6049163B2
(ja)
*
|
2008-07-21 |
2016-12-21 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
改善された治療上の特徴のための抗体の構造変異体
|
AU2009274512A1
(en)
|
2008-07-25 |
2010-01-28 |
The Regents Of The University Of Colorado |
Clip inhibitors and methods of modulating immune function
|
JP2011529962A
(ja)
|
2008-08-02 |
2011-12-15 |
ジェネンテック, インコーポレイテッド |
Iapのインヒビター
|
EP2307443B1
(en)
|
2008-08-07 |
2013-10-02 |
Yeda Research And Development Company Ltd. |
Affinity purification by cohesin-dockerin interaction
|
CA2736799A1
(en)
|
2008-08-25 |
2010-03-11 |
Burnham Institute For Medical Research |
Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
CA2735899A1
(en)
|
2008-09-25 |
2010-04-01 |
Cephalon, Inc. |
Liquid formulations of bendamustine
|
US8404239B2
(en)
|
2008-10-01 |
2013-03-26 |
Genentech, Inc. |
Anti-Notch2 NRR antibodies
|
AU2009312532B2
(en)
|
2008-11-06 |
2013-05-16 |
Ichnos Sciences SA |
Treatment with anti-alpha2 integrin antibodies
|
KR101807319B1
(ko)
|
2008-11-22 |
2017-12-11 |
제넨테크, 인크. |
유방암의 치료를 위한, 화학요법과 조합된 항-vegf 항체의 용도
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
CN109608545A
(zh)
|
2008-11-25 |
2019-04-12 |
健泰科生物技术公司 |
同等型特异性抗her4抗体
|
WO2010060920A1
(en)
|
2008-11-27 |
2010-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cxcl4l1 as a biomarker of pancreatic cancer
|
CN114835812A
(zh)
|
2008-12-09 |
2022-08-02 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
AU2009335788A1
(en)
|
2008-12-17 |
2011-07-07 |
Genentech, Inc. |
Hepatitis C virus combination therapy
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
US20110142836A1
(en)
*
|
2009-01-02 |
2011-06-16 |
Olav Mella |
B-cell depleting agents for the treatment of chronic fatigue syndrome
|
JP5828151B6
(ja)
|
2009-01-06 |
2018-09-19 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
アテローム性動脈硬化の処置のためのb細胞枯渇剤
|
SG172810A1
(en)
*
|
2009-01-15 |
2011-08-29 |
Cephalon Inc |
Novel forms of bendamustine free base
|
JP5936112B2
(ja)
|
2009-02-11 |
2016-06-15 |
アルブミディクス アクティーゼルスカブ |
アルブミン変異体及び複合体
|
DK3912643T3
(da)
|
2009-02-13 |
2022-10-17 |
Immunomedics Inc |
Immunokonjugater med en intracellulært-spaltelig binding
|
US20160095939A1
(en)
|
2014-10-07 |
2016-04-07 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
EP2402439B1
(en)
|
2009-02-27 |
2018-12-12 |
Order-made Medical Research Inc. |
A method for preparing a hybridoma cell by transplanting breast cancer cells
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
TWI461211B
(zh)
|
2009-03-20 |
2014-11-21 |
Genentech Inc |
抗-her抗體
|
HUE025726T2
(en)
|
2009-03-25 |
2016-04-28 |
Genentech Inc |
Anti-FGFR3 antibodies and their use
|
SG10201609416XA
(en)
|
2009-03-25 |
2016-12-29 |
Genentech Inc |
NOVEL ANTI-α5ß1 ANTIBODIES AND USES THEREOF
|
PE20120878A1
(es)
|
2009-04-01 |
2012-08-06 |
Genentech Inc |
ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
|
EP2414391B1
(en)
|
2009-04-02 |
2018-11-28 |
Roche Glycart AG |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
US9296785B2
(en)
|
2009-04-17 |
2016-03-29 |
Wake Forest University Health Sciences |
IL-13 receptor binding peptides
|
SG175305A1
(en)
|
2009-04-23 |
2011-11-28 |
Theraclone Sciences Inc |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
MX2011011670A
(es)
*
|
2009-05-01 |
2011-11-18 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual y usos de las mismas.
|
EP2427203B1
(en)
|
2009-05-05 |
2018-10-17 |
Novimmune S.A. |
Anti-il-17f antibodies and use thereof
|
EP2435476A4
(en)
|
2009-05-27 |
2013-04-17 |
Synageva Biopharma Corp |
ANTIBODIES OBTAINED FROM BIRDS
|
PL2437785T3
(pl)
|
2009-06-04 |
2015-08-31 |
Novartis Ag |
Sposoby identyfikacji miejsc sprzęgania IgG
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
EP2445925A1
(en)
|
2009-06-25 |
2012-05-02 |
Bristol-Myers Squibb Company |
Protein purification by caprylic acid (octanoic acid) precipitation
|
WO2011000054A1
(en)
|
2009-07-03 |
2011-01-06 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them
|
US8765431B2
(en)
|
2009-07-23 |
2014-07-01 |
The Regents Of The University Of Michigan |
Method for enzymatic production of decarboxylated polyketides and fatty acids
|
US20110027275A1
(en)
|
2009-07-31 |
2011-02-03 |
Napoleone Ferrara |
Inhibition of tumor metastasis
|
ES2793348T3
(es)
|
2009-08-11 |
2020-11-13 |
Hoffmann La Roche |
Producción de proteínas en medios de cultivo celular libres de glutamina
|
JP6088246B2
(ja)
|
2009-08-15 |
2017-03-01 |
ジェネンテック, インコーポレイテッド |
以前に治療された乳癌の治療のための抗血管新生療法
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
JP5887270B2
(ja)
|
2009-09-02 |
2016-03-16 |
ジェネンテック, インコーポレイテッド |
突然変異体smoothenedおよびその使用方法
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
RU2573915C2
(ru)
|
2009-09-16 |
2016-01-27 |
Дженентек, Инк. |
Содержащие суперспираль и/или привязку белковые комплексы и их применение
|
EP2478110B1
(en)
|
2009-09-16 |
2016-01-06 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
US20120178910A1
(en)
|
2009-09-23 |
2012-07-12 |
Medarex, Inc. |
Cation exchange chromatography (methods)
|
WO2011035456A1
(zh)
|
2009-09-25 |
2011-03-31 |
上海抗体药物国家工程研究中心有限公司 |
通过计算机辅助设计来获得高亲和力的蛋白质的方法
|
MX368790B
(es)
|
2009-10-15 |
2019-10-16 |
Genentech Inc |
Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
|
BR112012008833A2
(pt)
*
|
2009-10-15 |
2015-09-08 |
Abbott Lab |
imunoglobulinas de dominio variavel duplo e usos das mesmas
|
HUE026447T2
(en)
|
2009-10-16 |
2016-05-30 |
Novartis Ag |
Pharmacodynamic tumor response biomarkers
|
JP5889794B2
(ja)
|
2009-10-19 |
2016-03-22 |
ジェネンテック, インコーポレイテッド |
肝細胞増殖因子アクチベーターの調節
|
JP5814925B2
(ja)
|
2009-10-22 |
2015-11-17 |
ジェネンテック, インコーポレイテッド |
抗ヘプシン抗体及びその使用方法
|
RU2539772C2
(ru)
|
2009-10-22 |
2015-01-27 |
Дженентек, Инк. |
Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
KR101436219B1
(ko)
|
2009-10-26 |
2014-09-01 |
에프. 호프만-라 로슈 아게 |
글리코실화된 면역글로불린의 제조 방법
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
EP2325185A1
(en)
|
2009-10-28 |
2011-05-25 |
GPC Biotech AG |
Plk inhibitor
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
GB2488077A
(en)
|
2009-10-30 |
2012-08-15 |
Novozymes Biopharma Dk As |
Albumin variants
|
RU2585488C2
(ru)
|
2009-11-05 |
2016-05-27 |
Дженентек, Инк. |
Способы и композиция для секреции гетерологичных полипептидов
|
EP2496944A2
(en)
|
2009-11-05 |
2012-09-12 |
Novartis AG |
Biomarkers predictive of progression of fibrosis
|
WO2011062997A2
(en)
|
2009-11-17 |
2011-05-26 |
Musc Foundation For Research Development |
Human monoclonal antibodies to human nucleolin
|
CN103755809B
(zh)
|
2009-11-30 |
2016-06-01 |
霍夫曼-拉罗奇有限公司 |
治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
|
CN102711470A
(zh)
|
2009-12-01 |
2012-10-03 |
雅培制药有限公司 |
新的三环化合物
|
JP5607174B2
(ja)
|
2009-12-01 |
2014-10-15 |
アッヴィ・インコーポレイテッド |
新規な三環式化合物
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
WO2011068845A1
(en)
|
2009-12-02 |
2011-06-09 |
Immunomedics, Inc. |
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
|
KR20120123299A
(ko)
|
2009-12-04 |
2012-11-08 |
제넨테크, 인크. |
다중특이적 항체, 항체 유사체, 조성물 및 방법
|
DK2949670T3
(da)
|
2009-12-10 |
2019-05-13 |
Hoffmann La Roche |
Antistoffer, der fortrinsvis binder humant ekstracellulært CSF1R-domæne 4 og anvendelse deraf
|
EP2509626B1
(en)
|
2009-12-11 |
2016-02-10 |
F.Hoffmann-La Roche Ag |
Anti-vegf-c antibodies and methods using same
|
RU2017102553A
(ru)
|
2009-12-21 |
2018-12-19 |
Дженентек, Инк. |
Состав, содержащий антитело
|
WO2011075786A1
(en)
|
2009-12-23 |
2011-06-30 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them 2
|
ES2585350T3
(es)
|
2009-12-23 |
2016-10-05 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti Bv8 y usos de los mismos
|
EP3450459B1
(en)
|
2009-12-28 |
2021-05-26 |
OncoTherapy Science, Inc. |
Anti-cdh3 antibodies and uses thereof
|
WO2011082187A1
(en)
|
2009-12-30 |
2011-07-07 |
Genentech, Inc. |
Methods for modulating a pdgf-aa mediated biological response
|
EP2523680A4
(en)
*
|
2010-01-11 |
2013-06-19 |
Ct Molecular Med & Immunology |
REINFORCED CYTOTOXICITY OF ANTIBODIES TO CD74 AND HLA-DR WITH INTERFERON GAMMA
|
KR20130005264A
(ko)
|
2010-01-11 |
2013-01-15 |
알렉시온 파마슈티칼스, 인코포레이티드 |
항-cd200 항체들로 치료한 사람에게서 면역조절 효과의 생체지표들
|
US20120288499A1
(en)
|
2010-01-15 |
2012-11-15 |
Armand Bensussan |
Methods for diagnosis and treatment of cutaneous t cell lymphomas
|
WO2011097527A2
(en)
|
2010-02-04 |
2011-08-11 |
Xencor, Inc. |
Immunoprotection of therapeutic moieties using enhanced fc regions
|
TW201129383A
(en)
*
|
2010-02-10 |
2011-09-01 |
Immunogen Inc |
CD20 antibodies and uses thereof
|
JP5841072B2
(ja)
|
2010-02-10 |
2016-01-06 |
イミュノジェン・インコーポレーテッド |
Cd20抗体およびその使用
|
CN102770767A
(zh)
|
2010-02-10 |
2012-11-07 |
诺瓦提斯公司 |
用于肌肉生长的方法和组合物
|
BR112012020101A2
(pt)
|
2010-02-11 |
2018-09-25 |
Alexion Pharma Inc |
método diagnósticos e terapêuticos usando anticorpos anti-cd200.
|
PE20130041A1
(es)
|
2010-02-18 |
2013-01-28 |
Bristol Myers Squibb Co |
Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
|
US9556249B2
(en)
|
2010-02-18 |
2017-01-31 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
RU2545401C2
(ru)
|
2010-02-23 |
2015-03-27 |
Санофи |
Антитела к интегрину альфа-2 и их применения
|
AR080243A1
(es)
|
2010-02-23 |
2012-03-21 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
EP2539367A2
(en)
|
2010-02-23 |
2013-01-02 |
F. Hoffmann-La Roche AG |
Anti-angiogenesis therapy for the treatment of ovarian cancer
|
MX336682B
(es)
|
2010-03-05 |
2016-01-27 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humanos y usos de los mismos.
|
EP2542587A1
(en)
|
2010-03-05 |
2013-01-09 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r and uses thereof
|
NZ602040A
(en)
|
2010-03-24 |
2014-12-24 |
Genentech Inc |
Anti-lrp6 antibodies
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
CA2794708C
(en)
|
2010-03-29 |
2021-11-16 |
Zymeworks Inc. |
Antibodies with enhanced or suppressed effector function
|
PT3178851T
(pt)
|
2010-03-31 |
2020-07-17 |
Boehringer Ingelheim Int |
Anticorpos anti-cd40
|
EP2374816B1
(en)
|
2010-04-07 |
2016-09-28 |
Agency For Science, Technology And Research |
Binding molecules against Chikungunya virus and uses thereof
|
CN106977608A
(zh)
|
2010-04-09 |
2017-07-25 |
阿尔布麦狄克斯公司 |
白蛋白衍生物和变体
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
MA34209B1
(fr)
|
2010-04-13 |
2013-05-02 |
Bristol Myers Squibb Co |
Protéines à domaine de squelette basé sur la fibronectine qui se lient à pcsk9
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
MX346731B
(es)
|
2010-04-23 |
2017-03-30 |
Genentech Inc * |
Producción de proteínas heteromultiméricas.
|
SG185027A1
(en)
|
2010-05-03 |
2012-11-29 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
TW201138808A
(en)
|
2010-05-03 |
2011-11-16 |
Bristol Myers Squibb Co |
Serum albumin binding molecules
|
WO2011140151A1
(en)
|
2010-05-04 |
2011-11-10 |
Dyax Corp. |
Antibodies against epidermal growth factor receptor (egfr)
|
CN103189073B
(zh)
|
2010-05-04 |
2015-08-12 |
梅里麦克制药股份有限公司 |
抗表皮生长因子受体(egfr)的抗体及其用途
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
CA2799915C
(en)
|
2010-05-25 |
2023-09-26 |
Genentech, Inc. |
Methods of purifying polypeptides
|
CN103180339B
(zh)
|
2010-05-26 |
2016-04-27 |
百时美施贵宝公司 |
具有改善的稳定性的基于纤连蛋白的支架蛋白质
|
EP2808344A1
(en)
|
2010-06-01 |
2014-12-03 |
Monash University |
Antibodies directed to the receptor tyrosine kinase c-Met
|
EP3957653A1
(en)
|
2010-06-02 |
2022-02-23 |
Dana Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
KR20130098165A
(ko)
|
2010-06-03 |
2013-09-04 |
제넨테크, 인크. |
항체 및 면역접합체의 이뮤노-pet 영상화 및 그의 용도
|
KR101839163B1
(ko)
|
2010-06-08 |
2018-03-15 |
제넨테크, 인크. |
시스테인 조작된 항체 및 접합체
|
BR112012027995A2
(pt)
|
2010-06-18 |
2017-01-10 |
Genentech Inc |
anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
|
EP2582722A4
(en)
|
2010-06-19 |
2013-12-18 |
Sloan Kettering Inst Cancer |
ANTIBODIES AGAINST GD2
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
JP2013538191A
(ja)
|
2010-07-23 |
2013-10-10 |
トラスティーズ オブ ボストン ユニバーシティ |
病的血管新生および腫瘍細胞侵襲性の阻害のための治療法としてならびに分子イメージングおよび標的化送達のための抗DEsupR阻害剤
|
MX2013001302A
(es)
|
2010-08-03 |
2013-03-08 |
Hoffmann La Roche |
Biomarcadores de leucemia linfocitica (cll).
|
MX341579B
(es)
|
2010-08-03 |
2016-08-25 |
Abbvie Inc * |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
AU2011289275A1
(en)
|
2010-08-12 |
2013-02-21 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
JP5841149B2
(ja)
|
2010-08-13 |
2016-01-13 |
ロシュ グリクアート アーゲー |
抗テネイシンca2抗体及び使用の方法
|
CA2808185A1
(en)
|
2010-08-13 |
2012-02-16 |
Genentech, Inc. |
Antibodies to il-1.beta. and il-18, for treatment of disease
|
MY175341A
(en)
|
2010-08-13 |
2020-06-19 |
Roche Glycart Ag |
Anti-fap antibodies and methods of use
|
WO2012025530A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
EP2444484B1
(en)
|
2010-08-25 |
2019-02-06 |
Order-made Medical Research Inc. |
Method for producing antibodies using cancer cells
|
AU2011293253B2
(en)
|
2010-08-26 |
2014-12-11 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
PE20140190A1
(es)
|
2010-08-27 |
2014-02-10 |
Stem Centrx Inc |
Moduladores de proteinas notum y metodos de uso
|
DK2612151T3
(en)
|
2010-08-31 |
2017-10-02 |
Genentech Inc |
BIOMARKETS AND METHODS OF TREATMENT
|
WO2012030904A2
(en)
|
2010-08-31 |
2012-03-08 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
US9458231B2
(en)
|
2010-09-03 |
2016-10-04 |
Stemcentrx, Inc. |
Modulators and methods of use
|
KR102504750B1
(ko)
|
2010-09-29 |
2023-03-02 |
어젠시스 인코포레이티드 |
191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(adc)
|
CA2813466A1
(en)
|
2010-10-01 |
2012-04-05 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids that disrupt major groove binding partner interactions
|
EP2625197B1
(en)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CA2814029C
(en)
|
2010-10-08 |
2017-05-09 |
Shanghai Kexin Biotech Co., Ltd. |
Moesin fragments associated with immune thrombocytopenia
|
WO2012045274A1
(en)
|
2010-10-08 |
2012-04-12 |
Shanghai Kexin Biotech Co., Ltd. |
Moesin modulators and uses thereof
|
EP2624855B1
(en)
|
2010-10-08 |
2016-12-14 |
Shanghai Kexin Biotech Co., Ltd |
Moesin fragments associated with aplastic anemia
|
JP5913326B2
(ja)
|
2010-10-08 |
2016-04-27 |
シャンハイ クーシン バイオテック カンパニー,リミテッド |
モエシン断片の診断的および治療的使用
|
JP5868409B2
(ja)
|
2010-10-08 |
2016-02-24 |
シャンハイ クーシン バイオテック カンパニー,リミテッド |
モエシン断片およびその使用
|
EP3456740A1
(en)
|
2010-11-04 |
2019-03-20 |
Boehringer Ingelheim International GmbH |
Anti-il-23 antibodies
|
BR112013011305A2
(pt)
|
2010-11-08 |
2017-07-25 |
Chugai Pharmaceutical Co Ltd |
método de tratamento de uma disfunção mediada por il-6, método de tratamento de artrite reumatóide, artigo de fabricação, método de inibição da progressão de dano estrutural articular, composição farmacêutica, método de tratamento de artrite idiopática juvenil (jia) e método de tratamento de arterite de células gigantes (gca)
|
US8772457B2
(en)
|
2010-11-10 |
2014-07-08 |
Genentech, Inc. |
BACE1 antibodies
|
RU2018102375A
(ru)
|
2010-11-18 |
2019-02-21 |
Зе Дженерал Хоспитал Корпорейшен |
Новые композиции и применения антигипертензивных средств для терапии рака
|
EP2648748A1
(en)
|
2010-12-08 |
2013-10-16 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
JP6005657B2
(ja)
|
2010-12-16 |
2016-10-12 |
ジェネンテック, インコーポレイテッド |
Th2阻害に関連する診断及び治療
|
MX345519B
(es)
|
2010-12-20 |
2017-02-01 |
Genentech Inc |
Anticuerpos anti-mesotelina e inmunoconjugados.
|
CN103380143B
(zh)
|
2010-12-22 |
2016-01-06 |
百时美施贵宝公司 |
结合il-23的基于纤连蛋白的支架结构域蛋白质
|
KR101941514B1
(ko)
|
2010-12-22 |
2019-01-23 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
개선된 반감기를 가지는 변형된 항체
|
CA2820953A1
(en)
|
2010-12-22 |
2012-06-28 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
HUE035281T2
(en)
|
2011-01-14 |
2018-05-02 |
Univ California |
Therapeutic antibodies to ROR-1 protein and methods of their use
|
RU2018108836A
(ru)
|
2011-02-04 |
2019-03-14 |
Дженентек, Инк. |
ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
AU2012217867A1
(en)
|
2011-02-14 |
2013-09-05 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
JP2014515598A
(ja)
|
2011-03-10 |
2014-07-03 |
エイチシーオー アンティボディ, インク. |
二重特異性三鎖抗体様分子
|
AU2012225246B2
(en)
|
2011-03-10 |
2016-01-21 |
Omeros Corporation |
Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
MX2013010367A
(es)
|
2011-03-15 |
2014-04-14 |
Theraclone Sciences Inc |
Composiciones y metodos para la terapia y diagnostico de influenza.
|
TWI671315B
(zh)
|
2011-03-28 |
2019-09-11 |
法商賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
MX336740B
(es)
|
2011-03-29 |
2016-01-29 |
Roche Glycart Ag |
Variantes de fragmento cristalizable (fc) de los anticuerpos.
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
EP2694551A1
(en)
|
2011-04-07 |
2014-02-12 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
PT2697257T
(pt)
|
2011-04-13 |
2016-12-28 |
Bristol Myers Squibb Co |
Proteínas de fusão fc compreendendo novos ligantes ou arranjos
|
JP2014514313A
(ja)
|
2011-04-20 |
2014-06-19 |
ロシュ グリクアート アクチェンゲゼルシャフト |
血液脳関門のpH依存性通過のための方法及び構築物
|
EP2699597B1
(en)
|
2011-04-21 |
2016-06-01 |
Garvan Institute of Medical Research |
Modified variable domain molecules and methods for producing and using them b
|
EP2704751B1
(en)
|
2011-05-02 |
2019-04-17 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
US8852592B2
(en)
|
2011-05-10 |
2014-10-07 |
Biocare Medical, Llc |
Systems and methods for anti-PAX8 antibodies
|
RS56090B1
(sr)
|
2011-05-16 |
2017-10-31 |
Hoffmann La Roche |
Fgfr1 agonisti i načini primene
|
CN103842383B
(zh)
|
2011-05-16 |
2017-11-03 |
健能隆医药技术(上海)有限公司 |
多特异性fab融合蛋白及其使用方法
|
WO2012160530A1
(en)
|
2011-05-26 |
2012-11-29 |
Dr. Reddy's Laboratories Limited |
Purification of antibodies
|
US8691231B2
(en)
|
2011-06-03 |
2014-04-08 |
Merrimack Pharmaceuticals, Inc. |
Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
|
SI2714735T1
(sl)
|
2011-06-03 |
2021-12-31 |
Xoma Technology Ltd. |
Protitelesa, specifična za TGF-beta
|
ES2693647T3
(es)
|
2011-06-06 |
2018-12-13 |
Novo Nordisk A/S |
Anticuerpos terapéuticos
|
RU2011122942A
(ru)
|
2011-06-08 |
2012-12-20 |
Общество С Ограниченной Ответственностью "Асинэкс Медхим" |
Новые ингибиторы киназ
|
EP2537933A1
(en)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
An IL-15 and IL-15Ralpha sushi domain based immunocytokines
|
JP2014518080A
(ja)
|
2011-06-27 |
2014-07-28 |
バルネバ |
細胞のスクリーニング方法
|
CN107090038A
(zh)
|
2011-06-30 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
抗c‑met抗体配制剂
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
CN103827143A
(zh)
*
|
2011-07-06 |
2014-05-28 |
莫弗系统股份公司 |
抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
AR087364A1
(es)
*
|
2011-07-29 |
2014-03-19 |
Pf Medicament |
Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
|
WO2013025446A2
(en)
|
2011-08-12 |
2013-02-21 |
Omeros Corporation |
Anti-fzd10 monoclonal antibodies and methods for their use
|
WO2013025944A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition of angiogenesis in refractory tumors
|
EP2744824A1
(en)
|
2011-08-17 |
2014-06-25 |
F.Hoffmann-La Roche Ag |
Neuregulin antibodies and uses thereof
|
EP2747781B1
(en)
|
2011-08-23 |
2017-11-15 |
Roche Glycart AG |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
US9309306B2
(en)
|
2011-08-23 |
2016-04-12 |
Roche Glycart Ag |
Anti-MCSP antibodies
|
CN103781801B
(zh)
|
2011-08-23 |
2018-02-09 |
罗切格利卡特公司 |
包含两个Fab片段的无Fc的抗体及使用方法
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
MY170725A
(en)
|
2011-09-09 |
2019-08-27 |
Univ Osaka |
Dengue-virus serotype neutralizing antibodies
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
WO2013040433A1
(en)
|
2011-09-15 |
2013-03-21 |
Genentech, Inc. |
Methods of promoting differentiation
|
CA2846630A1
(en)
|
2011-09-19 |
2013-03-28 |
Genentech, Inc. |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
CN104302668A
(zh)
|
2011-09-23 |
2015-01-21 |
罗氏格黎卡特股份公司 |
双特异性的抗-egfr/抗igf-1r抗体
|
US20140234307A1
(en)
|
2011-09-27 |
2014-08-21 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
|
CN110511939A
(zh)
|
2011-10-03 |
2019-11-29 |
现代泰克斯公司 |
修饰的核苷、核苷酸和核酸及其用途
|
MX2014004074A
(es)
|
2011-10-05 |
2014-06-05 |
Genentech Inc |
Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
|
CN107266577B
(zh)
|
2011-10-11 |
2022-09-13 |
弗·哈夫曼-拉罗切有限公司 |
双特异性抗体的改进的组装
|
KR102102862B1
(ko)
|
2011-10-14 |
2020-04-22 |
제넨테크, 인크. |
항-HtrA1 항체 및 사용 방법
|
US9358250B2
(en)
|
2011-10-15 |
2016-06-07 |
Genentech, Inc. |
Methods of using SCD1 antagonists
|
US20140288279A1
(en)
|
2011-10-21 |
2014-09-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
M-DC8+ Monocyte Depleting Agent for the Prevention or the Treatment of a Condition Associated with a Chronic Hyperactivation of the Immune System
|
AU2012328819B2
(en)
|
2011-10-26 |
2017-08-03 |
Elanco Tiergesundheit Ag |
Monoclonal antibodies and methods of use
|
JP6184965B2
(ja)
|
2011-10-28 |
2017-08-23 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
ポリペプチド構築物およびその使用
|
KR20140097205A
(ko)
|
2011-10-28 |
2014-08-06 |
제넨테크, 인크. |
흑색종을 치료하는 치료 조합물 및 방법
|
JP2015504038A
(ja)
|
2011-10-31 |
2015-02-05 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
低減した免疫原性を有するフィブロネクチン結合ドメイン
|
RU2014121884A
(ru)
|
2011-11-02 |
2015-12-10 |
Дженентек, Инк. |
Хроматография перегрузки и элюирования
|
EP3536710A1
(en)
|
2011-11-16 |
2019-09-11 |
Boehringer Ingelheim International GmbH |
Anti il-36r antibodies
|
WO2013075066A2
(en)
|
2011-11-18 |
2013-05-23 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
BR112014012005A2
(pt)
|
2011-11-21 |
2017-12-19 |
Genentech Inc |
composições, métodos, formulação farmacêutica e artigo
|
US9988611B2
(en)
|
2011-12-01 |
2018-06-05 |
Ap Biosciences, Inc. |
Protein inhibitors to complement and VEGF pathways and methods of use thereof
|
CA2853138A1
(en)
|
2011-12-05 |
2013-06-13 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
JP6242804B2
(ja)
|
2011-12-15 |
2017-12-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトcsf−1rに対する抗体及びその使用
|
EP2791160B1
(en)
|
2011-12-16 |
2022-03-02 |
ModernaTX, Inc. |
Modified mrna compositions
|
WO2013096812A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Articles of manufacture and methods for co-administration of antibodies
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
CA2861610A1
(en)
|
2011-12-30 |
2013-07-04 |
Abbvie Inc. |
Dual specific binding proteins directed against il-13 and/or il-17
|
CA2863224A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
US20150011431A1
(en)
|
2012-01-09 |
2015-01-08 |
The Scripps Research Institute |
Humanized antibodies
|
EP2804630B1
(en)
|
2012-01-18 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Methods of using fgf19 modulators
|
IN2014DN05885A
(no)
|
2012-01-18 |
2015-06-05 |
Hoffmann La Roche |
|
MX2014009043A
(es)
|
2012-01-31 |
2014-10-14 |
Genentech Inc |
Anticuerpos anti-ige y sus metodos de uso.
|
US9567642B2
(en)
|
2012-02-02 |
2017-02-14 |
Massachusetts Institute Of Technology |
Methods and products related to targeted cancer therapy
|
EA034778B1
(ru)
|
2012-02-06 |
2020-03-19 |
Инхибркс, Инк. |
Антитела к cd47 и способы их применения
|
BR112014019579A2
(pt)
|
2012-02-10 |
2019-10-15 |
Genentech, Inc |
Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
|
KR102148303B1
(ko)
|
2012-02-11 |
2020-08-26 |
제넨테크, 인크. |
R-스폰딘 전위 및 그의 사용 방법
|
RU2624128C2
(ru)
|
2012-02-15 |
2017-06-30 |
Ф. Хоффманн-Ля Рош Аг |
Аффинная хроматография с применением fc-рецепторов
|
BR112014020826A8
(pt)
|
2012-02-24 |
2017-09-19 |
Stem Centrx Inc |
Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
|
CN104334580B
(zh)
|
2012-02-24 |
2018-03-30 |
艾伯维施特姆森特克斯有限责任公司 |
抗sez6抗体及使用方法
|
CN104736559B
(zh)
|
2012-03-16 |
2022-04-08 |
阿尔布梅迪克斯医疗有限公司 |
白蛋白变体
|
US9453076B2
(en)
|
2012-03-29 |
2016-09-27 |
Novimmune S.A. |
Anti-TLR4 antibodies and uses thereof
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
US10316103B1
(en)
|
2012-03-30 |
2019-06-11 |
Biocare Medical, Llc |
Systems and methods for anti-Uroplakin III antibodies
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
EP2833923A4
(en)
|
2012-04-02 |
2016-02-24 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
IN2014MN02164A
(no)
|
2012-04-27 |
2015-08-28 |
Cytomx Therapeutics Inc |
|
AR090903A1
(es)
|
2012-05-01 |
2014-12-17 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-pmel17
|
JP6473079B2
(ja)
|
2012-05-02 |
2019-02-20 |
ライフ テクノロジーズ コーポレーション |
高密度増殖およびトランスフェクション培地並びに発現増強物質の固有の組み合わせを用いる、哺乳類細胞における高収率一過性発現
|
US11078265B2
(en)
|
2012-05-03 |
2021-08-03 |
Boehringer Ingelheim International Gmbh |
Anti-IL-23 antibodies
|
US9441045B2
(en)
|
2012-05-04 |
2016-09-13 |
Dana-Farber Cancer Institute, Inc. |
Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
EP2861624A1
(en)
|
2012-06-15 |
2015-04-22 |
F. Hoffmann-La Roche AG |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
KR20150023906A
(ko)
|
2012-06-27 |
2015-03-05 |
에프. 호프만-라 로슈 아게 |
둘 이상의 상이한 표적 독립체를 함유하는 맞춤형의 선별적인 다중특이적 치료용 분자의 선별 및 제조 방법 및 그의 용도
|
BR112014032193A2
(pt)
|
2012-06-27 |
2017-06-27 |
Hoffmann La Roche |
métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico
|
CA2871882A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
KR102090849B1
(ko)
|
2012-07-04 |
2020-03-19 |
에프. 호프만-라 로슈 아게 |
공유 결합된 항원-항체 접합체
|
CN104411725B
(zh)
|
2012-07-04 |
2018-09-28 |
弗·哈夫曼-拉罗切有限公司 |
抗生物素抗体及使用方法
|
ES2600154T3
(es)
|
2012-07-04 |
2017-02-07 |
F. Hoffmann-La Roche Ag |
Anticuerpos antiteofilina y métodos de uso
|
EP2869851A1
(en)
|
2012-07-09 |
2015-05-13 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd22 antibodies
|
SG11201500096YA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti - cd79b antibodies
|
SG11201500093TA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti-cd79b antibodies
|
TW201406785A
(zh)
|
2012-07-09 |
2014-02-16 |
Genentech Inc |
抗cd22抗體及免疫結合物
|
HRP20211641T1
(hr)
|
2012-07-13 |
2022-02-04 |
Roche Glycart Ag |
Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
|
ES2771324T3
(es)
|
2012-08-03 |
2020-07-06 |
Dana Farber Cancer Inst Inc |
Usos médicos de agentes que modulan la activación de las células inmunitarias y métodos de detección correspondientes
|
US9315567B2
(en)
|
2012-08-14 |
2016-04-19 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
JP6302909B2
(ja)
|
2012-08-18 |
2018-03-28 |
アカデミア シニカAcademia Sinica |
シアリダーゼの同定および画像化のための細胞透過性プローブ
|
SG11201501286PA
(en)
|
2012-08-23 |
2015-05-28 |
Agensys Inc |
Antibody drug conjugates (adc) that bind to 158p1d7 proteins
|
CN108409856B
(zh)
|
2012-09-13 |
2022-03-04 |
百时美施贵宝公司 |
结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白
|
US10393733B2
(en)
|
2012-09-19 |
2019-08-27 |
Dana-Farber Cancer Institute, Inc. |
Dynamic BH3 profiling
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
ES2682345T3
(es)
|
2012-09-27 |
2018-09-20 |
Biocare Medical, Llc |
Sistemas y procedimientos de anticuerpos antiuroplaquina II
|
CN107892719B
(zh)
|
2012-10-04 |
2022-01-14 |
达纳-法伯癌症研究所公司 |
人单克隆抗-pd-l1抗体和使用方法
|
WO2014056783A1
(en)
|
2012-10-08 |
2014-04-17 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
TW202210507A
(zh)
|
2012-11-01 |
2022-03-16 |
美商艾伯維有限公司 |
抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
|
CA2890575C
(en)
|
2012-11-05 |
2021-11-09 |
Jumpei Enami |
Antibody and antibody composition production method
|
PE20150956A1
(es)
|
2012-11-08 |
2015-06-20 |
Hoffmann La Roche |
Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3
|
EP2917233A1
(en)
|
2012-11-08 |
2015-09-16 |
Novozymes Biopharma DK A/S |
Albumin variants
|
WO2014078268A2
(en)
|
2012-11-13 |
2014-05-22 |
Genentech, Inc. |
Anti-hemagglutinin antibodies and methods of use
|
KR20150084046A
(ko)
|
2012-11-15 |
2015-07-21 |
제넨테크, 인크. |
이온 강도-매개 pH 구배 이온 교환 크로마토그래피
|
TWI664192B
(zh)
|
2012-11-20 |
2019-07-01 |
法商賽諾菲公司 |
抗ceacam5抗體及其用途
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
RU2019118257A
(ru)
|
2012-12-03 |
2019-06-24 |
Новиммун С.А. |
Анти-cd47 антитела и способы их применения
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
ES2819573T3
(es)
|
2012-12-13 |
2021-04-16 |
Immunomedics Inc |
Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
PT2900277T
(pt)
|
2012-12-13 |
2022-05-25 |
Immunomedics Inc |
Doses de imunoconjugados de anticorpos e sn-38 para melhorar a eficácia e diminuir a toxicidade
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
WO2014100220A2
(en)
|
2012-12-18 |
2014-06-26 |
Biocare Medical, Llc |
Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
|
EA201690004A1
(ru)
|
2012-12-27 |
2016-07-29 |
Санофи |
Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
US20150361159A1
(en)
|
2013-02-01 |
2015-12-17 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
ES2944477T3
(es)
|
2013-02-06 |
2023-06-21 |
Inhibrx Inc |
Anticuerpos CD47 no reductores de plaquetas y no reductores de glóbulos rojos y métodos de uso de los mismos
|
JP2016509045A
(ja)
|
2013-02-22 |
2016-03-24 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを治療し、薬剤耐性を防止する方法
|
RS58873B1
(sr)
|
2013-02-22 |
2019-08-30 |
Abbvie Stemcentrx Llc |
Antidll3-antitelo-pbd konjugati i njihova upotreba
|
KR20150123811A
(ko)
|
2013-02-26 |
2015-11-04 |
로슈 글리카트 아게 |
항-mcsp 항체
|
DK2962113T3
(da)
|
2013-02-28 |
2019-07-01 |
Biocare Medical Llc |
Systemer og fremgangsmåder med anti-p40-antistoffer
|
JP2016510751A
(ja)
|
2013-03-06 |
2016-04-11 |
ジェネンテック, インコーポレイテッド |
抗がん剤耐性を治療及び予防する方法
|
EP2968587A2
(en)
|
2013-03-13 |
2016-01-20 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
|
US10653779B2
(en)
|
2013-03-13 |
2020-05-19 |
Genentech, Inc. |
Formulations with reduced oxidation
|
MX369671B
(es)
|
2013-03-13 |
2019-11-15 |
Genentech Inc |
Formulaciones con oxidacion reducida.
|
AR095398A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida
|
SG11201507475UA
(en)
|
2013-03-13 |
2015-10-29 |
Genentech Inc |
Antibody formulations
|
RU2707550C2
(ru)
|
2013-03-13 |
2019-11-27 |
Дженентек, Инк. |
Составы со сниженным окислением
|
CN105189552B
(zh)
|
2013-03-14 |
2019-08-02 |
基因泰克公司 |
抗b7-h4抗体和免疫缀合物
|
EP2968565A2
(en)
|
2013-03-14 |
2016-01-20 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
US9598485B2
(en)
|
2013-03-15 |
2017-03-21 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
EP2970471A2
(en)
|
2013-03-15 |
2016-01-20 |
F. Hoffmann-La Roche AG |
Anti-crth2 antibodies and their use
|
MX367668B
(es)
|
2013-03-15 |
2019-08-30 |
Dana Farber Cancer Inst Inc |
Anticuerpos neutralizadores de flavivirus y métodos de uso de los mismos.
|
KR20210037745A
(ko)
|
2013-03-15 |
2021-04-06 |
제넨테크, 인크. |
항산화제를 함유하는 세포 배양 조성물 및 폴리펩티드 생산 방법
|
MY197809A
(en)
|
2013-03-15 |
2023-07-18 |
Genentech Inc |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
US10035859B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
CA2903576C
(en)
|
2013-03-15 |
2021-06-08 |
Nai-Kong V. Cheung |
High affinity anti-gd2 antibodies
|
WO2014143739A2
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
MX2015011899A
(es)
|
2013-03-15 |
2016-05-05 |
Genentech Inc |
Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
|
RU2015144020A
(ru)
|
2013-03-15 |
2017-04-21 |
Дженентек, Инк. |
Среды для культивирования клеток и способы получения антител
|
CN105143264A
(zh)
|
2013-03-15 |
2015-12-09 |
豪夫迈·罗氏有限公司 |
用于肝癌诊断和治疗的组合物和方法
|
US9062108B2
(en)
|
2013-03-15 |
2015-06-23 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-1 and/or IL-17
|
RU2015147696A
(ru)
|
2013-04-09 |
2017-05-12 |
Бостон Байомедикал, Инк. |
Способы лечения злокачественной опухоли
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
RU2019108429A
(ru)
|
2013-04-29 |
2019-05-06 |
Ф. Хоффманн-Ля Рош Аг |
Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
|
WO2014179657A1
(en)
|
2013-05-03 |
2014-11-06 |
Eleven Biotherapeutics, Inc. |
Albumin variants binding to fcrn
|
AR096364A1
(es)
|
2013-05-20 |
2015-12-23 |
Genentech Inc |
Anticuerpos receptores de antitransferina y métodos de uso
|
BR112015030514A2
(pt)
|
2013-06-04 |
2017-08-29 |
Cytomx Therapeutics Inc |
Composições e métodos para conjugação de anticorpos ativáveis
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
EP3536699A1
(en)
|
2013-07-12 |
2019-09-11 |
F. Hoffmann-La Roche AG |
Elucidation of ion exchange chromatography input optimization
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
CN105814074B
(zh)
|
2013-07-18 |
2020-04-21 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
ES2683268T3
(es)
|
2013-07-25 |
2018-09-25 |
Cytomx Therapeutics, Inc. |
Anticuerpos multiespecíficos, anticuerpos activables multiespecíficos y métodos para usar los mismos
|
PL3027656T3
(pl)
*
|
2013-07-30 |
2019-10-31 |
Sbi Biotech Co Ltd |
Lek zawierający przeciwciało anty-fosfolipazowe D4
|
JP6510518B2
(ja)
|
2013-08-01 |
2019-05-08 |
アジェンシス,インコーポレイテッド |
Cd37タンパク質に結合する抗体薬物結合体(adc)
|
JP6463359B2
(ja)
|
2013-08-12 |
2019-01-30 |
ジェネンテック, インコーポレイテッド |
補体関連病態を治療するための組成物及び方法
|
CA2921398C
(en)
|
2013-08-14 |
2021-12-14 |
The Governing Council Of The University Of Toronto |
Antibodies for inhibiting frizzled receptors and pharmaceutical compositions containing antibodies for inhibiting frizzled receptors
|
ES2871418T3
(es)
|
2013-08-28 |
2021-10-28 |
Abbvie Stemcentrx Llc |
Composiciones y métodos de conjugación de anticuerpos específicos de sitio
|
EP3338793A1
(en)
|
2013-08-28 |
2018-06-27 |
AbbVie Stemcentrx LLC |
Novel sez6 modulators and methods of use
|
JP6602765B2
(ja)
|
2013-09-05 |
2019-11-06 |
ジェネンテック, インコーポレイテッド |
クロマトグラフィー再使用のための方法
|
CA2923579C
(en)
|
2013-09-06 |
2023-09-05 |
Academia Sinica |
Human inkt cell activation using glycolipids with altered glycosyl groups
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
JP6546178B2
(ja)
|
2013-09-13 |
2019-07-17 |
ジェネンテック, インコーポレイテッド |
細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法
|
MY176026A
(en)
|
2013-09-13 |
2020-07-22 |
Genentech Inc |
Methods and composions comprising purified recombinant polypeptides
|
JP2016537399A
(ja)
|
2013-09-17 |
2016-12-01 |
ジェネンテック, インコーポレイテッド |
抗lgr5抗体を使用する方法
|
JP6663852B2
(ja)
|
2013-09-19 |
2020-03-13 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Bh3プロファイリングの方法
|
NZ756892A
(en)
|
2013-09-25 |
2022-05-27 |
Cytomx Therapeutics Inc |
Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
|
EP3757130A1
(en)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
EA033817B1
(ru)
|
2013-09-27 |
2019-11-28 |
Genentech Inc |
Композиции, содержащие антитело к pdl1
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
DK3052522T3
(da)
|
2013-10-03 |
2020-02-24 |
Biocare Medical Llc |
Anti-sox 10 antistofsystemer og -fremgangsmåder
|
SG11201602503TA
(en)
|
2013-10-03 |
2016-04-28 |
Moderna Therapeutics Inc |
Polynucleotides encoding low density lipoprotein receptor
|
JP6534654B2
(ja)
|
2013-10-10 |
2019-06-26 |
ベス イスラエル デアコネス メディカル センター インコーポレイティッド |
Tm4sf1結合性タンパク質およびそれを使用する方法
|
EP3057615B1
(en)
|
2013-10-18 |
2021-02-24 |
F.Hoffmann-La Roche Ag |
Anti-rspo antibodies and methods of use
|
WO2015066279A2
(en)
|
2013-10-30 |
2015-05-07 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
AU2014343636A1
(en)
|
2013-11-04 |
2016-06-02 |
Glenmark Pharmaceuticals S.A. |
Production of T cell retargeting hetero-dimeric immunoglobulins
|
BR112016010051A2
(pt)
|
2013-11-04 |
2017-12-05 |
Pfizer |
?conjugados de anticorpo-fármaco anti-efna4?
|
KR20160070191A
(ko)
|
2013-11-06 |
2016-06-17 |
스템센트알엑스 인코포레이티드 |
신규한 항-클라우딘 항체 및 사용 방법
|
EP3070167A4
(en)
|
2013-11-06 |
2017-06-07 |
Osaka University |
Antibody having broad neutralizing activity in group 1 influenza a virus
|
CA2930243A1
(en)
|
2013-11-11 |
2015-05-14 |
Wake Forest University Health Sciences |
Epha3 and multi-valent targeting of tumors
|
AU2014363944B2
(en)
|
2013-12-09 |
2020-03-26 |
Allakos Inc. |
Anti-Siglec-8 antibodies and methods of use thereof
|
WO2015089283A1
(en)
|
2013-12-11 |
2015-06-18 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
TW201533060A
(zh)
|
2013-12-13 |
2015-09-01 |
Genentech Inc |
抗cd33抗體及免疫結合物
|
PT3083686T
(pt)
|
2013-12-17 |
2019-12-18 |
Hoffmann La Roche |
Métodos de tratamento de cancros com antagonistas da ligação ao eixo pd-1 e taxanos
|
AU2014364593A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
|
EP3083687A2
(en)
|
2013-12-17 |
2016-10-26 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
WO2015101586A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
EP3089759B1
(en)
|
2014-01-03 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Covalently linked polypeptide toxin-antibody conjugates
|
WO2015101587A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CA2937123A1
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
RU2016130349A
(ru)
|
2014-01-24 |
2018-03-01 |
Дженентек, Инк. |
Способы применения антител против steap1 и иммуноконъюгатов
|
EP3099715B1
(en)
|
2014-01-31 |
2020-11-18 |
Boehringer Ingelheim International GmbH |
Novel anti-baff antibodies
|
CN106459153B
(zh)
|
2014-01-31 |
2021-12-21 |
西托姆克斯治疗公司 |
蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
TR201810635T4
(tr)
|
2014-02-12 |
2018-08-27 |
Hoffmann La Roche |
Anti-jagged1 antikorları ve kullanım yöntemleri.
|
EP3107574A2
(en)
|
2014-02-21 |
2016-12-28 |
F. Hoffmann-La Roche AG |
Anti-il-13/il-17 bispecific antibodies and uses thereof
|
AU2015219495B2
(en)
|
2014-02-21 |
2019-11-21 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
AU2015218633A1
(en)
|
2014-02-21 |
2016-09-01 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibodies and drug conjugates for use in melanoma
|
US9139649B2
(en)
|
2014-02-25 |
2015-09-22 |
Immunomedics, Inc. |
Humanized anti-CD22 antibody
|
DK3110446T3
(da)
|
2014-02-28 |
2022-02-28 |
Allakos Inc |
Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
|
JP6293907B2
(ja)
|
2014-03-10 |
2018-03-14 |
リヒター ゲデオン エヌワイアールティー. |
プレクリーニング工程を用いた免疫グロブリンの精製
|
RU2748026C2
(ru)
|
2014-03-14 |
2021-05-19 |
Дженентек, Инк. |
Способы и композиции для секреции гетерологичных полипептидов
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
EP4043489A1
(en)
|
2014-03-19 |
2022-08-17 |
Dana-Farber Cancer Institute, Inc. |
Immunogenetic restriction on elicitation of antibodies
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
KR20220162886A
(ko)
|
2014-03-20 |
2022-12-08 |
브리스톨-마이어스 스큅 컴퍼니 |
혈청 알부민-결합 피브로넥틴 유형 iii 도메인
|
AU2015231210B2
(en)
|
2014-03-20 |
2019-09-12 |
Bristol-Myers Squibb Company |
Stabilized fibronectin based scaffold molecules
|
BR112016021383A2
(pt)
|
2014-03-24 |
2017-10-03 |
Genentech Inc |
Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
|
CN106415244B
(zh)
|
2014-03-27 |
2020-04-24 |
中央研究院 |
反应性标记化合物及其用途
|
CN103897059B
(zh)
*
|
2014-03-27 |
2016-03-23 |
中国人民解放军军事医学科学院生物工程研究所 |
抗cd20抗原的抗体l5h7及其应用
|
JP6588461B2
(ja)
|
2014-03-31 |
2019-10-09 |
ジェネンテック, インコーポレイテッド |
抗血管新生剤及びox40結合アゴニストを含む併用療法
|
DK3126394T3
(da)
|
2014-03-31 |
2020-01-13 |
Hoffmann La Roche |
Anti-OX40-antistoffer og fremgangsmåder til anvendelse
|
KR20160145813A
(ko)
|
2014-04-25 |
2016-12-20 |
다나-파버 캔서 인스티튜트 인크. |
중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법
|
RS61516B1
(sr)
|
2014-04-30 |
2021-03-31 |
Pfizer |
Konjugati anti-ptk7 antitelo-lek
|
KR20230164192A
(ko)
|
2014-05-06 |
2023-12-01 |
제넨테크, 인크. |
포유동물 세포를 사용한 이종다량체 단백질의 생산
|
CN106414499A
(zh)
|
2014-05-22 |
2017-02-15 |
基因泰克公司 |
抗gpc3抗体和免疫偶联物
|
JP2017524371A
(ja)
|
2014-05-23 |
2017-08-31 |
ジェネンテック, インコーポレイテッド |
Mitバイオマーカーとその使用方法
|
TWI717319B
(zh)
|
2014-05-27 |
2021-02-01 |
中央研究院 |
得自類桿菌屬之岩藻糖苷酶及其用途
|
EP4116329A1
(en)
|
2014-05-27 |
2023-01-11 |
Academia Sinica |
Anti-her2 glycoantibodies and uses thereof
|
EP3149036A4
(en)
|
2014-05-27 |
2017-12-27 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
TWI732738B
(zh)
|
2014-05-28 |
2021-07-11 |
中央研究院 |
抗TNF-α醣抗體及其用途
|
PT3148581T
(pt)
|
2014-05-30 |
2020-01-06 |
Henlix Biotech Co Ltd |
Anticorpos antirrecetor do fator de crescimento epidérmico (egfr)
|
CN107073121A
(zh)
|
2014-06-13 |
2017-08-18 |
基因泰克公司 |
治疗及预防癌症药物抗性的方法
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
EP3160504B1
(en)
|
2014-06-24 |
2020-09-16 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
MX2016015280A
(es)
|
2014-06-26 |
2017-03-03 |
Hoffmann La Roche |
Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
|
US9914774B2
(en)
|
2014-07-11 |
2018-03-13 |
Genentech, Inc. |
Notch pathway inhibition
|
BR112017000497B1
(pt)
|
2014-07-11 |
2023-12-26 |
Ventana Medical Systems, Inc |
Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
|
JP2017524359A
(ja)
|
2014-07-24 |
2017-08-31 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Il−23a関連疾患の処置に有用なバイオマーカー
|
US10669337B2
(en)
|
2014-07-25 |
2020-06-02 |
Cytomx Therapeutics, Inc. |
Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
|
WO2016016442A1
(en)
|
2014-08-01 |
2016-02-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
An anti-cd45rc antibody for use as drug
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
CN107074975A
(zh)
|
2014-08-28 |
2017-08-18 |
生物蛋白有限公司 |
用于修饰的t细胞的条件活性嵌合抗原受体
|
CA2960712A1
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
Human inkt cell activation using glycolipids
|
TW201625690A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
抗-cll-1抗體及免疫結合物
|
ES2830385T3
(es)
|
2014-09-12 |
2021-06-03 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-HER2
|
EP3191521A2
(en)
|
2014-09-12 |
2017-07-19 |
F. Hoffmann-La Roche AG |
Cysteine engineered antibodies and conjugates
|
CN113698488A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
ES2949173T3
(es)
|
2014-09-15 |
2023-09-26 |
Hoffmann La Roche |
Formulaciones de anticuerpo
|
BR112017004953A2
(pt)
|
2014-09-17 |
2017-12-05 |
Genentech Inc |
imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
|
ES2796903T3
(es)
|
2014-09-23 |
2020-11-30 |
Hoffmann La Roche |
Procedimiento de uso de inmunoconjugados anti-CD79b
|
WO2016054638A1
(en)
|
2014-10-03 |
2016-04-07 |
Dana-Farber Cancer Institute, Inc. |
Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
|
AU2015328273B2
(en)
|
2014-10-06 |
2020-09-17 |
Dana-Farber Cancer Institute, Inc. |
Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック, インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
WO2016070062A2
(en)
|
2014-10-31 |
2016-05-06 |
Genentech, Inc. |
Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same
|
CN106796235B
(zh)
|
2014-11-03 |
2021-01-29 |
豪夫迈·罗氏有限公司 |
用于检测t细胞免疫子集的测定法及其使用方法
|
AU2015343339A1
(en)
|
2014-11-03 |
2017-06-15 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment
|
US10738078B2
(en)
|
2014-11-03 |
2020-08-11 |
Bristol-Myers Squibb Company |
Use of caprylic acid precipitation for protein purification
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
BR112017008666A2
(pt)
|
2014-11-05 |
2018-01-30 |
Genentech, Inc. |
anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
|
MX2017005148A
(es)
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso.
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
CN107172879B
(zh)
|
2014-11-10 |
2021-11-05 |
豪夫迈·罗氏有限公司 |
抗白细胞介素-33抗体及其用途
|
EP3221360A1
(en)
|
2014-11-17 |
2017-09-27 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
CA2967820A1
(en)
|
2014-11-17 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods for tumor treatment using cd3xcd20 bispecific antibody
|
CN107108745B
(zh)
|
2014-11-19 |
2021-01-12 |
基因泰克公司 |
抗bace1的抗体和其用于神经疾病免疫疗法的用途
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
CN107250158B
(zh)
|
2014-11-19 |
2022-03-25 |
基因泰克公司 |
抗转铁蛋白受体/抗bace1多特异性抗体和使用方法
|
WO2016086021A1
(en)
|
2014-11-25 |
2016-06-02 |
Bristol-Myers Squibb Company |
Novel pd-l1 binding polypeptides for imaging
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
MY188799A
(en)
|
2014-12-05 |
2022-01-04 |
Genentech Inc |
Anti-cd79b antibodies and methods of use
|
AU2015360903B2
(en)
|
2014-12-08 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
|
BR112017011234A2
(pt)
|
2014-12-10 |
2018-03-27 |
Genentech Inc |
anticorpos contra receptor da barreira hematoencefálica e métodos de uso
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
WO2016096741A1
(en)
|
2014-12-17 |
2016-06-23 |
F. Hoffmann-La Roche Ag |
Novel methods for enzyme mediated polypeptide conjugation using sortase
|
EP3233921B1
(en)
|
2014-12-19 |
2021-09-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c5 antibodies and methods of use
|
ES2824151T3
(es)
|
2014-12-19 |
2021-05-11 |
Alkermes Inc |
Proteínas de fusión Fc monocatenarias
|
CA2973964A1
(en)
|
2015-01-16 |
2016-07-21 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
WO2016117346A1
(en)
|
2015-01-22 |
2016-07-28 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
TWI710571B
(zh)
|
2015-01-24 |
2020-11-21 |
中央研究院 |
腫瘤標記及其使用方法
|
CA2972072A1
(en)
|
2015-01-24 |
2016-07-28 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
CA2973886A1
(en)
|
2015-01-30 |
2016-08-04 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
CA2975875A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CA2972995A1
(en)
|
2015-02-04 |
2016-08-11 |
Boehringer Ingelheim International Gmbh |
Methods of treating inflammatory diseases
|
CN114773470A
(zh)
|
2015-02-05 |
2022-07-22 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
|
MD1009Z
(ro)
*
|
2015-03-02 |
2016-09-30 |
Алёна НИКОРИЧ |
Metodă de determinare a predispunerii persoanei la dezvoltarea limfomului non-Hodgkin
|
WO2016141230A1
(en)
|
2015-03-05 |
2016-09-09 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
MX2017011644A
(es)
|
2015-03-13 |
2017-12-04 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
|
CA2978095C
(en)
|
2015-03-13 |
2022-02-15 |
Bristol-Myers Squibb Company |
Use of alkaline washes during chromatography to remove impurities
|
US20180105555A1
(en)
|
2015-03-20 |
2018-04-19 |
Bristol-Myers Squibb Company |
Use of dextran for protein purification
|
RU2021124437A
(ru)
|
2015-04-03 |
2021-09-29 |
Еурека Терапьютикс, Инк. |
Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования
|
CN107709364A
(zh)
|
2015-04-07 |
2018-02-16 |
豪夫迈·罗氏有限公司 |
具有激动剂活性的抗原结合复合体及使用方法
|
CA2981969C
(en)
|
2015-04-08 |
2023-12-05 |
Dana-Farber Cancer Institute, Inc. |
Humanized influenza monoclonal antibodies and methods of use thereof
|
BR112017018574A2
(pt)
|
2015-04-14 |
2018-04-17 |
Boehringer Ingelheim International Gmbh |
métodos para o tratamento de doenças
|
JP6851978B2
(ja)
|
2015-04-20 |
2021-03-31 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ミトコンドリアプロファイリングによるアルボシジブ応答の予測
|
CA2981543A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
KR20170138558A
(ko)
|
2015-04-24 |
2017-12-15 |
비브 헬스케어 유케이 (넘버5) 리미티드 |
Hiv 융합을 표적으로 하는 폴리펩티드
|
PL3286315T3
(pl)
|
2015-04-24 |
2021-11-02 |
F. Hoffmann-La Roche Ag |
Sposoby identyfikacji bakterii zawierających polipeptydy wiążące
|
MX2017013482A
(es)
|
2015-04-24 |
2018-03-01 |
Genentech Inc |
Proteinas multiespecificas de union al antigeno.
|
AU2016253957C1
(en)
|
2015-04-27 |
2021-04-01 |
Dana-Farber Cancer Institute, Inc. |
High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells
|
EP3778640A1
(en)
|
2015-05-01 |
2021-02-17 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
EP3288977B1
(en)
|
2015-05-01 |
2021-11-17 |
Dana-Farber Cancer Institute, Inc. |
Methods of mediating cytokine expression with anti ccr4 antibodies
|
CA2984945A1
(en)
|
2015-05-04 |
2016-11-10 |
Cytomx Therapeutics, Inc. |
Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
|
DK3292150T3
(da)
|
2015-05-04 |
2020-04-27 |
Cytomx Therapeutics Inc |
Aktiverbare anti-cd166-antistoffer og fremgangsmåder til anvendelse deraf
|
BR112017023868A2
(pt)
|
2015-05-04 |
2018-07-24 |
Cytomx Therapeutics Inc |
anticorpos anti-itga3, anticorpos anti-itga3 ativáveis, e métodos de uso dos mesmos
|
WO2016179518A2
(en)
|
2015-05-06 |
2016-11-10 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
WO2016183104A1
(en)
|
2015-05-11 |
2016-11-17 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
MX2017014381A
(es)
|
2015-05-12 |
2018-03-02 |
Genentech Inc |
Metodos terapeuticos y diagnosticos para cancer.
|
WO2016187068A1
(en)
|
2015-05-15 |
2016-11-24 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
TR201911032T4
(tr)
|
2015-05-18 |
2019-08-21 |
Tolero Pharmaceuticals Inc |
Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları.
|
CA2987403A1
(en)
|
2015-05-28 |
2016-12-01 |
Genentech, Inc. |
Cell-based assay for detecting anti-cd3 homodimers
|
EP3763827A1
(en)
|
2015-05-29 |
2021-01-13 |
F. Hoffmann-La Roche AG |
Pd-l1 promoter methylation in cancer
|
PL3303632T5
(pl)
|
2015-05-29 |
2023-07-03 |
F. Hoffmann-La Roche Ag |
Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
|
EP3302563A1
(en)
|
2015-05-29 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Humanized anti-ebola virus glycoprotein antibodies and methods of use
|
CN114656573A
(zh)
|
2015-05-30 |
2022-06-24 |
分子模板公司 |
去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
|
EA201792623A1
(ru)
|
2015-06-03 |
2018-04-30 |
Бостон Биомедикал, Инк. |
Композиции, содержащие ингибитор стволовости рака и иммунотерапевтический агент, для применения в лечении рака
|
CN107849124B
(zh)
|
2015-06-05 |
2021-09-24 |
基因泰克公司 |
抗tau抗体及使用方法
|
WO2016200836A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
EP3303397A1
(en)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
US10501545B2
(en)
|
2015-06-16 |
2019-12-10 |
Genentech, Inc. |
Anti-CLL-1 antibodies and methods of use
|
EP3310811B1
(en)
|
2015-06-16 |
2021-06-16 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
UA124615C2
(uk)
|
2015-06-16 |
2021-10-20 |
Дженентек, Інк. |
АНТИТІЛО ПРОТИ ПОДІБНОГО ДО Fc-РЕЦЕПТОРА БІЛКА 5 (FcRH5)
|
WO2016205567A1
(en)
|
2015-06-17 |
2016-12-22 |
Allakos Inc. |
Methods and compositions for treating fibrotic diseases
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
AU2016280159A1
(en)
|
2015-06-17 |
2017-12-07 |
Genentech, Inc. |
Anti-HER2 antibodies and methods of use
|
RS62986B1
(sr)
|
2015-06-24 |
2022-03-31 |
Hoffmann La Roche |
Antitela na transferinski receptor sa prilagođenim afinitetom
|
PT3313443T
(pt)
|
2015-06-25 |
2023-08-30 |
Immunomedics Inc |
Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
|
US10669528B2
(en)
|
2015-06-25 |
2020-06-02 |
Children's Medical Center Corporation |
Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
JP2018520153A
(ja)
|
2015-06-29 |
2018-07-26 |
ジェネンテック, インコーポレイテッド |
臓器移植における使用のためのii型抗cd20抗体
|
ES2878316T3
(es)
|
2015-06-29 |
2021-11-18 |
Ventana Med Syst Inc |
Materiales y procedimientos para realizar ensayos histoquímicos de pro-epirregulina y anfirregulina humanas
|
EP3316885B1
(en)
|
2015-07-01 |
2021-06-23 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
CN107922961A
(zh)
|
2015-07-13 |
2018-04-17 |
生命技术公司 |
用于cho细胞中经改善的瞬时蛋白质表达的系统和方法
|
RU2759963C2
(ru)
|
2015-08-03 |
2021-11-19 |
Сумитомо Даиниппон Фарма Онколоджи, Инк. |
Комбинированные терапии для лечения рака
|
TW202340452A
(zh)
|
2015-08-04 |
2023-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
HU231463B1
(hu)
|
2015-08-04 |
2024-01-28 |
Richter Gedeon Nyrt. |
Módszer rekombináns proteinek galaktóz tartalmának növelésére
|
KR20180030917A
(ko)
|
2015-08-05 |
2018-03-26 |
얀센 바이오테크 인코포레이티드 |
항-cd154 항체 및 그의 사용 방법
|
US10509035B2
(en)
|
2015-08-07 |
2019-12-17 |
Gamamabs Pharma Sa |
Antibodies, antibody drug conjugates and methods of use
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
US11098079B2
(en)
|
2015-08-13 |
2021-08-24 |
Amgen Inc. |
Charged depth filtration of antigen-binding proteins
|
EP3337816B1
(en)
|
2015-08-20 |
2024-02-14 |
Albumedix Ltd |
Albumin variants and conjugates
|
WO2017040342A1
(en)
|
2015-08-28 |
2017-03-09 |
Genentech, Inc. |
Anti-hypusine antibodies and uses thereof
|
AR105910A1
(es)
|
2015-09-04 |
2017-11-22 |
Obi Pharma Inc |
Matrices de glicano y método de uso
|
TWI799366B
(zh)
|
2015-09-15 |
2023-04-21 |
美商建南德克公司 |
胱胺酸結骨架平臺
|
TWI811716B
(zh)
|
2015-09-18 |
2023-08-11 |
德商百靈佳殷格翰國際股份有限公司 |
治療發炎性疾病之方法
|
JP7002446B2
(ja)
|
2015-09-21 |
2022-03-04 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
Cd3結合ポリペプチド
|
JP6904947B2
(ja)
|
2015-09-22 |
2021-07-21 |
スプリング バイオサイエンス コーポレーション |
抗ox40抗体及びその診断用途
|
RU2763916C2
(ru)
|
2015-09-23 |
2022-01-11 |
Дженентек, Инк. |
Оптимизированные варианты анти-vegf антител
|
JP6893504B2
(ja)
|
2015-09-23 |
2021-06-23 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
速い解離速度を有する血清アルブミン結合フィブロネクチンタイプiiiドメイン
|
WO2017053619A1
(en)
|
2015-09-23 |
2017-03-30 |
Bristrol-Myers Squibb Company |
Glypican-3binding fibronectin based scafflold molecules
|
EP3662930A1
(en)
|
2015-09-24 |
2020-06-10 |
AbVitro LLC |
Hiv antibody compositions and methods of use
|
CN108026560A
(zh)
|
2015-09-25 |
2018-05-11 |
豪夫迈·罗氏有限公司 |
在低共熔溶剂中使用分选酶的转酰胺反应
|
WO2017050889A1
(en)
|
2015-09-25 |
2017-03-30 |
F. Hoffmann-La Roche Ag |
Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof
|
WO2017050874A1
(en)
|
2015-09-25 |
2017-03-30 |
F. Hoffmann-La Roche Ag |
Process for producing thioesters employing a sortase a
|
JP6998862B2
(ja)
|
2015-09-25 |
2022-02-04 |
エフ.ホフマン-ラ ロシュ アーゲー |
可溶性ソルターゼa
|
EP3355914B1
(en)
|
2015-09-29 |
2024-03-06 |
The General Hospital Corporation |
A composition comprising bcg for reducing cholesterol.
|
US20190048089A1
(en)
|
2015-09-30 |
2019-02-14 |
Janssen Biotech, Inc. |
Antagonistic Antibodies Specifically Binding Human CD40 and Methods of Use
|
PL3356404T3
(pl)
|
2015-10-02 |
2022-01-03 |
F. Hoffmann-La Roche Ag |
Przeciwciała anty-pd1 i sposoby ich stosowania
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
SI3356411T1
(sl)
|
2015-10-02 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Bispecifična protitelesa, specifična za PD1 in TIM3
|
TWI747843B
(zh)
|
2015-10-02 |
2021-12-01 |
瑞士商赫孚孟拉羅股份公司 |
雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
|
IL293708A
(en)
|
2015-10-06 |
2022-08-01 |
Genentech Inc |
A method for treating multiple sclerosis
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
WO2017066561A2
(en)
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11780848B2
(en)
|
2015-10-16 |
2023-10-10 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
SG10201913993QA
(en)
|
2015-10-16 |
2020-03-30 |
Abbvie Inc |
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
ES2904553T3
(es)
|
2015-10-30 |
2022-04-05 |
Hoffmann La Roche |
Fragmentos de anticuerpo modificados con bisagra y procedimientos de preparación
|
CN108697791B
(zh)
|
2015-11-03 |
2022-08-23 |
詹森生物科技公司 |
特异性结合pd-1的抗体及其用途
|
JP6998869B2
(ja)
|
2015-11-08 |
2022-02-04 |
ジェネンテック, インコーポレイテッド |
多重特異性抗体のスクリーニング方法
|
US10946106B2
(en)
|
2015-11-30 |
2021-03-16 |
The Regents Of The University Of California |
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
|
KR20180085740A
(ko)
|
2015-12-09 |
2018-07-27 |
에프. 호프만-라 로슈 아게 |
항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
EP3390442B1
(en)
|
2015-12-18 |
2023-11-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c5 antibodies and methods of use
|
WO2017106630A1
(en)
|
2015-12-18 |
2017-06-22 |
The General Hospital Corporation |
Polyacetal polymers, conjugates, particles and uses thereof
|
AU2016380988B2
(en)
|
2015-12-30 |
2022-07-21 |
Genentech, Inc. |
Formulations with reduced degradation of polysorbate
|
WO2017117304A1
(en)
|
2015-12-30 |
2017-07-06 |
Genentech, Inc. |
Use of tryptophan derivatives for protein formulations
|
IL259588B2
(en)
|
2016-01-08 |
2023-09-01 |
Hoffmann La Roche |
Methods for the treatment of cea-positive cancer using pd-1 spindle-binding antagonists and bispecific antibodies against anti-cea and anti-cd3
|
EP3408671B1
(en)
|
2016-01-25 |
2023-11-01 |
F. Hoffmann-La Roche AG |
Methods for assaying t-cell dependent bispecific antibodies
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
CA3011372A1
(en)
|
2016-02-10 |
2017-08-17 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
WO2017151502A1
(en)
|
2016-02-29 |
2017-09-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
WO2017148880A1
(en)
|
2016-03-01 |
2017-09-08 |
F. Hoffmann-La Roche Ag |
Obinutuzumab variants having altered cell death induction
|
CA3016170A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
BR112018067923A2
(pt)
|
2016-03-15 |
2019-02-05 |
Chugai Pharmaceutical Co Ltd |
métodos de tratamento de cânceres usando antagonistas de ligação de eixo pd-1 e anticorpos anti-gpc3
|
AU2017234163B2
(en)
|
2016-03-15 |
2023-01-19 |
Mersana Therapeutics, Inc. |
NaPi2b-targeted antibody-drug conjugates and methods of use thereof
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
EP3429603B1
(en)
|
2016-03-15 |
2021-12-29 |
Children's Medical Center Corporation |
Methods and compositions relating to hematopoietic stem cell expansion
|
TWI780045B
(zh)
|
2016-03-29 |
2022-10-11 |
台灣浩鼎生技股份有限公司 |
抗體、醫藥組合物及方法
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
WO2017167712A1
(en)
|
2016-03-30 |
2017-10-05 |
F. Hoffmann-La Roche Ag |
Improved sortase
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
AU2017250583A1
(en)
|
2016-04-15 |
2018-08-16 |
Boehringer Ingelheim International Gmbh |
Methods of treating inflammatory diseases
|
WO2017181152A2
(en)
|
2016-04-15 |
2017-10-19 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
KR20230051601A
(ko)
|
2016-04-15 |
2023-04-18 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Icos 리간드 변이체 면역조절 단백질 및 그의 용도
|
ES2850428T3
(es)
|
2016-04-15 |
2021-08-30 |
Hoffmann La Roche |
Procedimientos de monitorización y tratamiento del cáncer
|
AU2017248644B2
(en)
|
2016-04-15 |
2019-10-31 |
Bioatla, Llc |
Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
CN109311977B
(zh)
|
2016-04-15 |
2022-06-14 |
H.伦德贝克公司 |
人源化的抗pacap抗体及其用途
|
WO2017181079A2
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
JP2019522960A
(ja)
|
2016-04-21 |
2019-08-22 |
アッヴィ・ステムセントルクス・エル・エル・シー |
新規の抗bmpr1b抗体及び使用方法
|
KR20230110820A
(ko)
|
2016-04-22 |
2023-07-25 |
오비아이 파머 인코퍼레이티드 |
글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
|
CN109310385A
(zh)
|
2016-04-27 |
2019-02-05 |
免疫医疗公司 |
抗trop-2-sn-38抗体药物缀合物用于检查点抑制剂复发/难治的肿瘤的疗法的功效
|
CN109071635B
(zh)
|
2016-05-02 |
2023-09-01 |
豪夫迈·罗氏有限公司 |
Contorsbody-单链靶标结合物
|
EP3455252B1
(en)
|
2016-05-11 |
2022-02-23 |
F. Hoffmann-La Roche AG |
Modified anti-tenascin antibodies and methods of use
|
IL262404B2
(en)
|
2016-05-13 |
2024-04-01 |
Bioatla Llc |
Antibodies, Antibody Fragments and Their Immunomodules Against ROR2 and Their Uses
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
WO2017210335A1
(en)
|
2016-06-01 |
2017-12-07 |
Bristol-Myers Squibb Company |
Imaging methods using 18f-radiolabeled biologics
|
EP3463486A1
(en)
|
2016-06-01 |
2019-04-10 |
Bristol-Myers Squibb Company |
Pet imaging with pd-l1 binding polypeptides
|
TW201902512A
(zh)
|
2016-06-02 |
2019-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療方法
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
MA45186A
(fr)
|
2016-06-03 |
2019-04-10 |
Janssen Biotech Inc |
Domaines de fibronectine de type iii se liant à l'albumine sérique
|
AR108800A1
(es)
|
2016-06-17 |
2018-09-26 |
Genentech Inc |
Purificación de anticuerpos multiespecíficos
|
CN109690315A
(zh)
|
2016-07-08 |
2019-04-26 |
豪夫迈·罗氏有限公司 |
人附睾蛋白4(he4)用于评估muc16阳性癌症治疗的响应性的用途
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
IL296127A
(en)
|
2016-07-22 |
2022-11-01 |
Dana Farber Cancer Inst Inc |
Antibodies to the glucocorticoid-induced tumor necrosis factor receptor and methods of using them
|
MA45715A
(fr)
|
2016-07-25 |
2019-05-29 |
Biogen Ma Inc |
Anticorps anti-hspa5 (grp78) et leurs utilisations
|
CA3032049C
(en)
|
2016-07-27 |
2023-11-07 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
CA3032120A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
MX2019001184A
(es)
|
2016-07-29 |
2019-09-26 |
Juno Therapeutics Inc |
Anticuerpos anti-idiotípicos y métodos relacionados.
|
EP3491026A4
(en)
|
2016-07-29 |
2020-07-29 |
OBI Pharma, Inc. |
HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
|
JP2019530434A
(ja)
|
2016-08-05 |
2019-10-24 |
ジェネンテック, インコーポレイテッド |
アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
|
CN116271014A
(zh)
|
2016-08-05 |
2023-06-23 |
中外制药株式会社 |
用于预防或治疗il-8相关疾病的组合物
|
JP7250674B2
(ja)
|
2016-08-08 |
2023-04-03 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療及び診断方法
|
CN109790201A
(zh)
|
2016-08-12 |
2019-05-21 |
百时美施贵宝公司 |
纯化蛋白质的方法
|
JP7286536B2
(ja)
|
2016-08-15 |
2023-06-05 |
ジェネンテック, インコーポレイテッド |
非イオン性サーファクタント及びポリペプチドを含む組成物中の非イオン性サーファクタントを定量するためのクロマトグラフィー法
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
JP7138094B2
(ja)
|
2016-08-25 |
2022-09-15 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
マクロファージ活性化剤と組み合わせた抗csf-1r抗体の間欠投与
|
AU2017321973A1
(en)
|
2016-09-02 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
WO2018045245A1
(en)
|
2016-09-02 |
2018-03-08 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
EP3509633A1
(en)
|
2016-09-06 |
2019-07-17 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating or preventing zika virus infection
|
TW201825674A
(zh)
|
2016-09-09 |
2018-07-16 |
美商艾斯合顧問有限公司 |
表現雙特異性接合分子的溶瘤病毒
|
EP3509616A1
(en)
|
2016-09-09 |
2019-07-17 |
H. Hoffnabb-La Roche Ag |
Selective peptide inhibitors of frizzled
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
RU2752832C2
(ru)
|
2016-09-16 |
2021-08-09 |
Шанхай Хенлиус Байотек, Инк. |
Анти-pd-1 антитела
|
JP6976315B2
(ja)
|
2016-09-19 |
2021-12-08 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
補体因子に基づくアフィニティークロマトグラフィー
|
KR20240035625A
(ko)
|
2016-09-21 |
2024-03-15 |
넥스트큐어 인코포레이티드 |
Siglec-15를 위한 항체 및 이의 사용 방법
|
KR20190072528A
(ko)
|
2016-10-06 |
2019-06-25 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
US20180105588A1
(en)
|
2016-10-14 |
2018-04-19 |
Boehringer Ingelheim International Gmbh |
Methods of treating diseases
|
WO2018081649A1
(en)
|
2016-10-28 |
2018-05-03 |
Banyan Biomarkers, Inc. |
Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック, インコーポレイテッド |
抗mic抗体及び使用方法
|
JP7039582B2
(ja)
|
2016-11-03 |
2022-03-22 |
ブリストル-マイヤーズ スクイブ カンパニー |
活性化可能な抗ctla-4抗体およびその使用
|
AU2017353936A1
(en)
|
2016-11-04 |
2019-05-02 |
Novimmune Sa |
Anti-CD19 antibodies and methods of use thereof
|
WO2018089807A2
(en)
|
2016-11-11 |
2018-05-17 |
The Regents Of The University Of California |
Anti-cd46 antibodies and methods of use
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
KR102221364B1
(ko)
|
2016-11-21 |
2021-03-04 |
쿠레아브 게엠베하 |
항-gp73 항체 및 면역접합체
|
EP3541414A4
(en)
|
2016-11-21 |
2020-11-11 |
OBI Pharma, Inc. |
CONJUGATE BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND PROCESSES
|
US11299469B2
(en)
|
2016-11-29 |
2022-04-12 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
CN117820467A
(zh)
|
2016-12-07 |
2024-04-05 |
基因泰克公司 |
抗tau抗体和使用方法
|
CA3044679A1
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
EP3362471B1
(en)
|
2016-12-19 |
2021-11-17 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Profiling peptides and methods for sensitivity profiling
|
WO2018115051A1
(en)
|
2016-12-22 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
|
TW201833140A
(zh)
|
2017-01-09 |
2018-09-16 |
美商莫瑞麥克製藥公司 |
抗fgfr抗體及使用方法
|
TW201831517A
(zh)
|
2017-01-12 |
2018-09-01 |
美商優瑞科生物技術公司 |
靶向組織蛋白h3肽/mhc複合體之構築體及其用途
|
MX2019009485A
(es)
|
2017-02-10 |
2019-11-05 |
Genentech Inc |
Anticuerpos contra triptasa, composiciones de estos y usos de estos.
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
US20180271996A1
(en)
|
2017-02-28 |
2018-09-27 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
MX2019010295A
(es)
|
2017-03-01 |
2019-11-21 |
Genentech Inc |
Métodos de diagnóstico y terapéuticos para el cáncer.
|
US20180303952A1
(en)
|
2017-03-09 |
2018-10-25 |
Cytomx Therapeutics, Inc. |
Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
DK3596116T3
(da)
|
2017-03-16 |
2023-11-27 |
Alpine Immune Sciences Inc |
Variante immunmodulatoriske pd-l1-proteiner og anvendelser deraf
|
AU2018235835A1
(en)
|
2017-03-16 |
2019-09-05 |
Alpine Immune Sciences, Inc. |
PD-L2 variant immunomodulatory proteins and uses thereof
|
BR112019018747A2
(pt)
|
2017-03-16 |
2020-05-05 |
Alpine Immune Sciences Inc |
proteínas imunomoduladoras variantes de cd80 e usos das mesmas
|
CA3057808A1
(en)
|
2017-03-24 |
2018-09-27 |
Zenyaku Kogyo Co., Ltd. |
Anti-igm/b cell surface antigen bispecific antibody
|
EP3600283A4
(en)
|
2017-03-27 |
2020-12-16 |
Immunomedics, Inc. |
TREATMENT OF TROP-2 EXPRESSIVE TRIPLE NEGATIVE BREAST CANCER WITH SACITUZUMAB GOVITECAN AND A RAD51 INHIBITOR
|
US20180273627A1
(en)
|
2017-03-27 |
2018-09-27 |
Boehringer Ingelheim International Gmbh |
Anti il-36r antibodies combination therapy
|
CN117205311A
(zh)
|
2017-03-28 |
2023-12-12 |
基因泰克公司 |
治疗神经退行性疾病的方法
|
EP3601343B1
(en)
|
2017-03-30 |
2022-05-04 |
ECS-Progastrin SA |
Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
|
US11561225B2
(en)
|
2017-03-30 |
2023-01-24 |
Progastrine Et Cancers S.À R.L. |
Compositions and methods for treating lung cancer
|
CN108588126B
(zh)
|
2017-03-31 |
2020-04-10 |
北京百奥赛图基因生物技术有限公司 |
Cd47基因人源化改造动物模型的制备方法及应用
|
CN110352201A
(zh)
|
2017-04-03 |
2019-10-18 |
免疫医疗公司 |
用于癌症疗法的抗体药物缀合物的皮下施用
|
SG11201909218RA
(en)
|
2017-04-03 |
2019-11-28 |
Hoffmann La Roche |
Antibodies binding to steap-1
|
MX2019011138A
(es)
|
2017-04-12 |
2020-01-27 |
Magenta Therapeutics Inc |
Antagonistas del receptor de hidrocarburo de arilo y sus usos.
|
WO2018191389A1
(en)
|
2017-04-12 |
2018-10-18 |
Roche Sequencing Solutions, Inc. |
A method for sequencing reaction with tagged nucleoside obtained via pictet spengler reaction
|
EP3615569A1
(en)
|
2017-04-25 |
2020-03-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
CA3059820A1
(en)
|
2017-04-26 |
2018-11-01 |
Eureka Therapeutics, Inc. |
Constructs specifically recognizing glypican 3 and uses thereof
|
CN110799541A
(zh)
|
2017-04-27 |
2020-02-14 |
特沙诺有限公司 |
针对淋巴细胞活化基因-3(lag-3)的抗体药剂及其用途
|
TW201842929A
(zh)
|
2017-05-03 |
2018-12-16 |
美商必治妥美雅史谷比公司 |
結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
|
BR112019022912A2
(pt)
|
2017-05-05 |
2020-05-26 |
Allakos Inc. |
Métodos e composições para tratar doenças oculares alérgicas
|
US10543271B2
(en)
|
2017-05-12 |
2020-01-28 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
US10646464B2
(en)
|
2017-05-17 |
2020-05-12 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
AU2018272311A1
(en)
|
2017-05-26 |
2019-12-19 |
Novimmune Sa |
Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
|
AU2018278327B2
(en)
|
2017-06-01 |
2023-03-16 |
Cytomx Therapeutics, Inc. |
Activatable anti-pdl1 antibodies and methods of use thereof
|
US10793634B2
(en)
|
2017-06-09 |
2020-10-06 |
Boehringer Ingelheim International Gmbh |
Anti-TrkB antibodies
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
|
EP3655779A1
(en)
|
2017-07-20 |
2020-05-27 |
CytomX Therapeutics, Inc. |
Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof
|
KR20200093518A
(ko)
|
2017-07-21 |
2020-08-05 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
MX2020001493A
(es)
|
2017-08-08 |
2020-03-24 |
Hoffmann La Roche |
Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de celulas b grandes difusas (dlbcl).
|
WO2019028555A1
(en)
|
2017-08-09 |
2019-02-14 |
University Of Saskatchewan |
HER3 BINDING AGENTS AND USES THEREOF
|
KR20200037366A
(ko)
|
2017-08-11 |
2020-04-08 |
제넨테크, 인크. |
항-cd8 항체 및 이의 용도
|
US10759865B2
(en)
|
2017-08-22 |
2020-09-01 |
Eyal Levit |
Treatment of diabetes mellitus
|
KR20200058406A
(ko)
|
2017-08-30 |
2020-05-27 |
싸이톰스 테라퓨틱스, 인크. |
활성화 가능한 항-cd166 항체 및 이의 사용 방법
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
WO2019053272A1
(en)
|
2017-09-15 |
2019-03-21 |
King's College London |
COMPOSITIONS AND METHODS FOR IMPROVING T GAMMA DELTA LYMPHOCYTES IN INTESTINE
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
CA3198255A1
(en)
|
2017-10-10 |
2019-04-18 |
Alpine Immune Sciences, Inc. |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
AU2018347521A1
(en)
|
2017-10-12 |
2020-05-07 |
Immunowake Inc. |
VEGFR-antibody light chain fusion protein
|
WO2019075417A1
(en)
|
2017-10-14 |
2019-04-18 |
Abbvie Inc. |
CONJUGATES OF MEDICAMENT ANTI-CD71 ACTIVATED ANTIBODIES AND METHODS OF USE
|
AU2018347607A1
(en)
|
2017-10-14 |
2020-03-26 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
AU2018351000B2
(en)
|
2017-10-18 |
2023-11-30 |
Alpine Immune Sciences, Inc. |
Variant ICOS Ligand immunomodulatory proteins and related compositions and methods
|
WO2019077113A1
(en)
|
2017-10-20 |
2019-04-25 |
F. Hoffmann-La Roche Ag |
COPY PROTECTION FOR ANTIBODIES
|
MX2020004100A
(es)
|
2017-10-30 |
2020-07-24 |
Hoffmann La Roche |
Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
|
CN111683669A
(zh)
|
2017-10-31 |
2020-09-18 |
美真达治疗公司 |
用于造血干细胞和祖细胞移植疗法的组合物和方法
|
AU2018358241A1
(en)
|
2017-10-31 |
2020-05-07 |
Edigene Biotechnology, Inc. |
Compositions and methods for the expansion of hematopoietic stem and progenitor cells
|
EP3703688A2
(en)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
WO2019086395A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Trifab-contorsbody
|
WO2019086394A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
The compbody - a multivalent target binder
|
JP2021502066A
(ja)
|
2017-11-06 |
2021-01-28 |
ジェネンテック, インコーポレイテッド |
がんの診断及び療法
|
CA3084687C
(en)
|
2017-12-05 |
2024-01-02 |
Progastrine Et Cancers S.A R.L. |
Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
|
JP2021507717A
(ja)
|
2017-12-18 |
2021-02-25 |
ビーブ、ヘルスケア、ユーケー、(ナンバー5)、リミテッドViiv Healthcare Uk (No.5) Limited |
抗原結合性ポリペプチド
|
US11802154B2
(en)
|
2017-12-20 |
2023-10-31 |
Alexion Pharmaceuticals, Inc. |
Humanized anti-CD200 antibodies and uses thereof
|
EP3728317A2
(en)
|
2017-12-21 |
2020-10-28 |
F. Hoffmann-La Roche AG |
Antibodies binding to hla-a2/wt1
|
JP7314146B2
(ja)
|
2017-12-28 |
2023-07-25 |
中外製薬株式会社 |
細胞傷害誘導治療剤
|
US11905327B2
(en)
|
2017-12-28 |
2024-02-20 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against TIGIT
|
JP7436365B2
(ja)
|
2017-12-29 |
2024-02-21 |
エフ. ホフマン-ラ ロシュ アーゲー |
抗vegf抗体及び使用の方法
|
US20200338132A1
(en)
|
2018-01-03 |
2020-10-29 |
Magenta Therapeutics Inc. |
Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
|
US20200385758A1
(en)
|
2018-01-05 |
2020-12-10 |
Ottawa Hospital Research Institute |
Modified vaccinia vectors
|
US11713353B2
(en)
|
2018-01-15 |
2023-08-01 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against PD-1
|
US20200339686A1
(en)
|
2018-01-16 |
2020-10-29 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
AU2019218959A1
(en)
|
2018-02-08 |
2020-09-03 |
Genentech, Inc. |
Bispecific antigen-binding molecules and methods of use
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
AU2019225249A1
(en)
|
2018-02-26 |
2020-09-17 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-PD-L1 antagonist antibodies
|
WO2019173771A1
(en)
|
2018-03-09 |
2019-09-12 |
Cytomx Therapeutics, Inc. |
Activatable cd147 antibodies and methods of making and use thereof
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
CN112166123B
(zh)
|
2018-03-14 |
2022-09-30 |
北京轩义医药科技有限公司 |
抗紧密连接蛋白18.2抗体
|
MX2020009296A
(es)
|
2018-03-15 |
2020-11-13 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso.
|
KR20230042407A
(ko)
|
2018-03-29 |
2023-03-28 |
제넨테크, 인크. |
포유류 세포들에서 젖분비자극 활성의 조절
|
CN112313248A
(zh)
|
2018-03-29 |
2021-02-02 |
百时美施贵宝公司 |
纯化单体单克隆抗体的方法
|
CA3093034A1
(en)
|
2018-03-30 |
2019-10-03 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against lag-3 and uses thereof
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
IT201800004253A1
(it)
|
2018-04-05 |
2019-10-05 |
|
Composizioni e metodi per il trattamento della tachicardia ventricolare polimorfa catecolaminergica dominante ereditaria.
|
TW202344272A
(zh)
|
2018-04-13 |
2023-11-16 |
美商建南德克公司 |
穩定抗cd79b免疫結合物調配物
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
EP3788071A1
(en)
|
2018-05-02 |
2021-03-10 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
WO2019222294A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
EP4242238A3
(en)
|
2018-05-14 |
2023-12-06 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
EP3802609A2
(en)
|
2018-05-24 |
2021-04-14 |
Janssen Biotech, Inc. |
Psma binding agents and uses thereof
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
WO2020006176A1
(en)
|
2018-06-27 |
2020-01-02 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
WO2020006347A1
(en)
|
2018-06-29 |
2020-01-02 |
Boehringer Ingelheim International Gmbh |
Anti-cd40 antibodies for use in treating autoimmune disease
|
WO2020018879A1
(en)
|
2018-07-20 |
2020-01-23 |
Surface Oncology, Inc. |
Anti-cd112r compositions and methods
|
EP3829642A1
(en)
|
2018-07-31 |
2021-06-09 |
Amgen Inc. |
Pharmaceutical formulations of masked antibodies
|
EP3833389A1
(en)
|
2018-08-08 |
2021-06-16 |
Genentech, Inc. |
Use of tryptophan derivatives and l-methionine for protein formulation
|
CA3108693A1
(en)
|
2018-08-10 |
2020-02-13 |
Ashutosh Sharma |
Method of preparing an antibody pharmaceutical formulation
|
AR114550A1
(es)
|
2018-08-10 |
2020-09-16 |
Chugai Pharmaceutical Co Ltd |
Moléculas de unión al antígeno anti-cd137 y sus usos
|
MA53493A
(fr)
|
2018-08-31 |
2021-07-07 |
Alx Oncology Inc |
Polypeptides leurres
|
MX2021002190A
(es)
|
2018-08-31 |
2021-05-14 |
Regeneron Pharma |
Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20.
|
KR20210071976A
(ko)
|
2018-09-04 |
2021-06-16 |
마젠타 테라퓨틱스 인코포레이티드 |
아릴 하이드로카본 수용체 길항제 및 사용 방법
|
KR20210089143A
(ko)
|
2018-09-18 |
2021-07-15 |
메리맥 파마슈티컬즈, 인크. |
항-tnfr2 항체 및 그의 용도
|
CN112955747A
(zh)
|
2018-09-19 |
2021-06-11 |
豪夫迈·罗氏有限公司 |
膀胱癌的治疗和诊断方法
|
ES2955032T3
(es)
|
2018-09-21 |
2023-11-28 |
Hoffmann La Roche |
Métodos de diagnóstico para el cáncer de mama triple negativo
|
JP7425049B2
(ja)
|
2018-09-25 |
2024-01-30 |
ハープーン セラピューティクス,インク. |
Dll3結合タンパク質および使用方法
|
JP2022502088A
(ja)
|
2018-09-27 |
2022-01-11 |
エクシリオ デベロップメント, インコーポレイテッド |
マスクされたサイトカインポリペプチド
|
CN113164780A
(zh)
|
2018-10-10 |
2021-07-23 |
泰洛斯治疗公司 |
抗lap抗体变体及其用途
|
EP3864127A1
(en)
|
2018-10-10 |
2021-08-18 |
Boehringer Ingelheim International GmbH |
Method for membrane gas transfer in high density bioreactor culture
|
KR102262012B1
(ko)
|
2018-10-15 |
2021-06-09 |
연세대학교 산학협력단 |
생산성이 향상된 항체 및 이의 제조방법
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
MX2021004348A
(es)
|
2018-10-18 |
2021-05-28 |
Genentech Inc |
Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
|
JP2022506108A
(ja)
|
2018-10-23 |
2022-01-17 |
グリカルディアル ダイアグノスティクス エセ. エレ. |
グリコシル化ApoJに特異的な抗体およびその使用
|
RU2724469C2
(ru)
|
2018-10-31 |
2020-06-23 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с cd20
|
CA3118445A1
(en)
|
2018-11-02 |
2020-05-07 |
Cytomx Therapeutics, Inc. |
Activatable anti-cd166 antibodies and methods of use thereof
|
HUP1800376A2
(hu)
|
2018-11-07 |
2020-05-28 |
Richter Gedeon Nyrt |
Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
|
US11279698B2
(en)
|
2018-11-20 |
2022-03-22 |
Cornell University |
Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
|
JP2022510276A
(ja)
|
2018-11-30 |
2022-01-26 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Cd86バリアント免疫調節タンパク質およびその使用
|
US11034710B2
(en)
|
2018-12-04 |
2021-06-15 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
WO2020117257A1
(en)
|
2018-12-06 |
2020-06-11 |
Genentech, Inc. |
Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
|
CN113271956A
(zh)
|
2018-12-06 |
2021-08-17 |
西托姆克斯治疗公司 |
基质金属蛋白酶可裂解的和丝氨酸或半胱氨酸蛋白酶可裂解的底物及其使用方法
|
CN113660944A
(zh)
|
2018-12-11 |
2021-11-16 |
Q32生物公司 |
用于补体相关疾病的融合蛋白构建体
|
AR117453A1
(es)
|
2018-12-20 |
2021-08-04 |
Genentech Inc |
Fc de anticuerpos modificados y métodos para utilizarlas
|
AU2019403313A1
(en)
|
2018-12-21 |
2021-07-15 |
Genentech, Inc. |
Methods of producing polypeptides using a cell line resistant to apoptosis
|
MX2021007307A
(es)
|
2018-12-21 |
2021-07-07 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3.
|
JP2022516881A
(ja)
|
2018-12-26 |
2022-03-03 |
キシリオ ディベロップメント インコーポレイテッド |
抗ctla4抗体およびその使用方法
|
AU2020211974A1
(en)
|
2019-01-22 |
2021-08-05 |
Genentech, Inc. |
Immunoglobulin a antibodies and methods of production and use
|
EP3914615A1
(en)
|
2019-01-23 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Methods of producing multimeric proteins in eukaryotic host cells
|
JPWO2020153467A1
(ja)
|
2019-01-24 |
2021-12-02 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
EP3917570A1
(en)
|
2019-01-29 |
2021-12-08 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
MX2021009514A
(es)
|
2019-02-07 |
2021-11-04 |
Sanofi Sa |
Uso de inmunoconjugados anti-ceacam5 para el tratamiento del cancer de pulmon.
|
EP3693023A1
(en)
|
2019-02-11 |
2020-08-12 |
Sanofi |
Use of anti-ceacam5 immunoconjugates for treating lung cancer
|
CN113874394B
(zh)
|
2019-02-20 |
2024-01-19 |
和铂抗体有限公司 |
抗体
|
WO2020176672A1
(en)
|
2019-02-26 |
2020-09-03 |
Cytomx Therapeutics, Inc. |
Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
|
JP2022521773A
(ja)
|
2019-02-27 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬
|
EP3930846A1
(en)
|
2019-03-01 |
2022-01-05 |
Merrimack Pharmaceuticals, Inc. |
Anti-tnfr2 antibodies and uses thereof
|
WO2020185479A1
(en)
|
2019-03-08 |
2020-09-17 |
Boehringer Ingelheim International Gmbh |
Anti-il-36r antibody formulations
|
JP2022524074A
(ja)
|
2019-03-14 |
2022-04-27 |
ジェネンテック, インコーポレイテッド |
抗HER2 MABと組み合わせたHER2xCD3二重特異性抗体によるがんの処置
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
AU2020248645A1
(en)
|
2019-03-27 |
2021-10-28 |
Tigatx, Inc. |
Engineered IgA antibodies and methods of use
|
US20220042954A1
(en)
|
2019-03-29 |
2022-02-10 |
Bristol-Myers Squibb Company |
Methods of measuring hydrophobicity of chromatographic resins
|
HUP1900112A1
(hu)
|
2019-04-04 |
2020-10-28 |
Richter Gedeon Nyrt |
Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelõzõ flokkulálás alkalmazásával
|
EP3956664A1
(en)
|
2019-04-18 |
2022-02-23 |
Genentech, Inc. |
Antibody potency assay
|
KR20220002967A
(ko)
|
2019-04-19 |
2022-01-07 |
제넨테크, 인크. |
항 mertk 항체 및 이의 사용 방법
|
AR118720A1
(es)
|
2019-04-19 |
2021-10-27 |
Janssen Biotech Inc |
Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
|
MX2021012506A
(es)
|
2019-04-19 |
2022-01-24 |
Chugai Pharmaceutical Co Ltd |
Receptor quimerico que reconoce un sitio modificado geneticamente en anticuerpo.
|
PE20220287A1
(es)
|
2019-05-09 |
2022-02-25 |
Boehringer Ingelheim Int |
Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
|
CN114206340A
(zh)
|
2019-05-14 |
2022-03-18 |
豪夫迈·罗氏有限公司 |
使用抗cd79b免疫缀合物治疗滤泡性淋巴瘤的方法
|
BR112021022666A2
(pt)
|
2019-05-14 |
2022-03-29 |
Werewolf Therapeutics Inc |
Frações de separação e seus métodos e uso
|
TW202112799A
(zh)
|
2019-06-05 |
2021-04-01 |
美商建南德克公司 |
過載層析管柱之再生方法
|
CN114245802A
(zh)
|
2019-06-20 |
2022-03-25 |
石药集团巨石生物制药有限公司 |
修饰的il-2蛋白、peg偶联物及其用途
|
TW202115112A
(zh)
|
2019-06-27 |
2021-04-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗-angpt2抗體
|
WO2021006328A1
(en)
|
2019-07-10 |
2021-01-14 |
Chugai Seiyaku Kabushiki Kaisha |
Claudin-6 binding molecules and uses thereof
|
JPWO2021010326A1
(no)
|
2019-07-12 |
2021-01-21 |
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
JP2022542863A
(ja)
|
2019-07-24 |
2022-10-07 |
ハー・ルンドベック・アクチエゼルスカベット |
抗mGluR5抗体及びその使用
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
EP4003526A2
(en)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
Antibodies binding to gprc5d
|
CN114174338A
(zh)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
DE102019121007A1
(de)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Antigenbindende Proteine, die spezifisch an MAGE-A binden
|
US20210032370A1
(en)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Recruiting agent further binding an mhc molecule
|
WO2021024209A1
(en)
|
2019-08-06 |
2021-02-11 |
Aprinoia Therapeutics Inc. |
Antibodies that bind to pathological tau species and uses thereof
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
WO2021046159A1
(en)
|
2019-09-04 |
2021-03-11 |
Genentech, Inc. |
Cd8 binding agents and uses thereof
|
MX2022003212A
(es)
|
2019-09-18 |
2022-04-25 |
Genentech Inc |
Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso.
|
CN114650844A
(zh)
|
2019-09-23 |
2022-06-21 |
西托姆克斯治疗公司 |
抗cd47抗体、可活化抗cd47抗体及其使用方法
|
TW202126685A
(zh)
|
2019-09-24 |
2021-07-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗nrp1a抗體及其用於治療眼或眼部疾病之用途
|
CR20220127A
(es)
|
2019-09-27 |
2022-05-27 |
Genentech Inc |
Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
MX2022003935A
(es)
|
2019-10-04 |
2022-04-25 |
Tae Life Sciences Llc |
Composiciones de anticuerpo que comprenden mutaciones fc y propiedades de conjugacion especificas del sitio.
|
PE20221039A1
(es)
|
2019-10-18 |
2022-06-17 |
Genentech Inc |
METODOS PARA USAR INMUNOCONJUGADOS ANTI-CD79b PARA TRATAR LINFOMA DIFUSO DE LINFOCITOS B GRANDES
|
US20220389103A1
(en)
|
2019-11-06 |
2022-12-08 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
CN114641270A
(zh)
|
2019-11-15 |
2022-06-17 |
豪夫迈·罗氏有限公司 |
防止水性蛋白质溶液中可见颗粒的形成
|
WO2021113780A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
|
JP2023504740A
(ja)
|
2019-12-06 |
2023-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
Bcma標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
|
CR20230210A
(es)
|
2019-12-13 |
2023-06-14 |
Genentech Inc |
ANTICUERPOS ANTI-LY6G6D Y MÉTODOS DE USO (Divisional 2022-0330)
|
US20210230278A1
(en)
|
2019-12-18 |
2021-07-29 |
Hoffmann-La Roche Inc. |
Antibodies binding to HLA-A2/MAGE-A4
|
EP4081294A2
(en)
|
2019-12-23 |
2022-11-02 |
Genentech, Inc. |
Apolipoprotein l1-specific antibodies and methods of use
|
AU2019479791A1
(en)
|
2019-12-27 |
2022-07-14 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
WO2021141996A1
(en)
|
2020-01-06 |
2021-07-15 |
Cytomx Therapeutics, Inc. |
Single- and multi-chain polypeptides that bind specifically to cd3 epsilon
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
US20230132241A1
(en)
|
2020-01-15 |
2023-04-27 |
Immatics Biotechnologies Gmbh |
Antigen binding proteins specifically binding prame
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021155129A1
(en)
|
2020-01-31 |
2021-08-05 |
Seagen Inc. |
Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
JP2023515633A
(ja)
|
2020-02-28 |
2023-04-13 |
ブリストル-マイヤーズ スクイブ カンパニー |
放射性標識されたフィブロネクチンに基づく足場および抗体ならびにそのセラノスティクス的使用
|
JP2023516952A
(ja)
|
2020-02-28 |
2023-04-21 |
ジェンザイム・コーポレーション |
最適化された薬物コンジュゲーションのための改変された結合ポリペプチド
|
GB202003632D0
(en)
|
2020-03-12 |
2020-04-29 |
Harbour Antibodies Bv |
SARS-Cov-2 (SARS2, COVID-19) antibodies
|
CN115605507A
(zh)
|
2020-03-13 |
2023-01-13 |
基因泰克公司(Us) |
抗白介素-33抗体及其用途
|
CN117551194A
(zh)
|
2020-03-19 |
2024-02-13 |
基因泰克公司 |
同种型选择性抗TGF-β抗体及使用方法
|
CN115315512A
(zh)
|
2020-03-26 |
2022-11-08 |
基因泰克公司 |
具有降低的宿主细胞蛋白质的经修饰的哺乳动物细胞
|
IL296789A
(en)
|
2020-03-31 |
2022-11-01 |
Repertoire Immune Medicines Inc |
Barcoded exchangeable peptide-mhc multimer libraries
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
WO2021207449A1
(en)
|
2020-04-09 |
2021-10-14 |
Merck Sharp & Dohme Corp. |
Affinity matured anti-lap antibodies and uses thereof
|
EP4133085A1
(en)
|
2020-04-10 |
2023-02-15 |
CytomX Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
BR112022020497A2
(pt)
|
2020-04-24 |
2022-12-06 |
Sanofi Sa |
Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e folfox
|
BR112022020592A2
(pt)
|
2020-04-24 |
2022-11-29 |
Sanofi Sa |
Combinações antitumor contendo conjugados de anticorpo anti-ceacam5, trifluridina e tipiracila
|
IL297541A
(en)
|
2020-04-24 |
2022-12-01 |
Genentech Inc |
Methods for using anti-cd79b immunoconjugates
|
KR20230005176A
(ko)
|
2020-04-24 |
2023-01-09 |
사노피 |
항-ceacam5 항체 콘쥬게이트 및 세툭시맙을 함유하는 항종양 조합물
|
MX2022013402A
(es)
|
2020-04-24 |
2022-11-14 |
Sanofi Sa |
Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y folfiri.
|
JP2023523450A
(ja)
|
2020-04-28 |
2023-06-05 |
ジェネンテック, インコーポレイテッド |
非小細胞肺がん免疫療法のための方法及び組成物
|
EP4146797A1
(en)
|
2020-05-06 |
2023-03-15 |
Orchard Therapeutics (Europe) Limited |
Treatment for neurodegenerative diseases
|
CN115605184A
(zh)
|
2020-05-15 |
2023-01-13 |
豪夫迈·罗氏有限公司(Ch) |
防止胃肠外蛋白质溶液中的可见颗粒形成
|
CN115605185A
(zh)
|
2020-05-19 |
2023-01-13 |
豪夫迈·罗氏有限公司(Ch) |
螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途
|
GB202007842D0
(en)
|
2020-05-26 |
2020-07-08 |
Quell Therapeutics Ltd |
Polypeptide useful in adoptive cell therapy
|
AU2021280232A1
(en)
|
2020-05-26 |
2022-12-15 |
Boehringer Ingelheim International Gmbh |
Anti-PD-1 antibodies
|
CA3183808A1
(en)
|
2020-06-11 |
2021-12-16 |
Genentech, Inc. |
Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same
|
WO2021252977A1
(en)
|
2020-06-12 |
2021-12-16 |
Genentech, Inc. |
Methods and compositions for cancer immunotherapy
|
CA3181820A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
CA3181672A1
(en)
|
2020-06-18 |
2021-12-23 |
Shi Li |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
AR122656A1
(es)
|
2020-06-19 |
2022-09-28 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 / folr1
|
BR112022025574A2
(pt)
|
2020-06-19 |
2023-01-03 |
Hoffmann La Roche |
Anticorpos que se ligam a cd3, polinucleotídeo isolado, célula hospedeira, método para produzir um anticorpo que se liga a cd3 e para tratar uma doença em um indivíduo, composição farmacêutica, anticorpo para uso e invenção
|
US11780920B2
(en)
|
2020-06-19 |
2023-10-10 |
Hoffmann-La Roche Inc. |
Antibodies binding to CD3 and CD19
|
WO2021262783A1
(en)
|
2020-06-24 |
2021-12-30 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
WO2022006562A1
(en)
|
2020-07-03 |
2022-01-06 |
Dana-Farber Cancer Institute, Inc. |
Multispecific coronavirus antibodies
|
JP2023532764A
(ja)
|
2020-07-07 |
2023-07-31 |
エフ. ホフマン-ラ ロシュ アーゲー |
治療用タンパク質製剤の安定剤としての代替界面活性剤
|
JP2023532768A
(ja)
|
2020-07-07 |
2023-07-31 |
バイオエヌテック エスエー |
Hpv陽性癌の治療用rna
|
BR112023000428A2
(pt)
|
2020-07-10 |
2023-03-14 |
Inst Nat Sante Rech Med |
Métodos e composições para tratar epilepsia
|
TW202204895A
(zh)
|
2020-07-13 |
2022-02-01 |
美商建南德克公司 |
預測多肽免疫性的基於細胞之方法
|
AU2021308653A1
(en)
|
2020-07-17 |
2023-02-16 |
Genentech, Inc. |
Anti-Notch2 antibodies and methods of use
|
CN116171324A
(zh)
|
2020-07-20 |
2023-05-26 |
丹娜法伯癌症研究院 |
用于治疗和预防冠状病毒感染的方法和组合物
|
US20230324408A1
(en)
|
2020-08-05 |
2023-10-12 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
WO2022031876A1
(en)
|
2020-08-07 |
2022-02-10 |
Genentech, Inc. |
Flt3 ligand fusion proteins and methods of use
|
WO2022031948A1
(en)
|
2020-08-07 |
2022-02-10 |
Genentech, Inc. |
T cell-based methods for predicting polypeptide immunogenicity
|
CN116419747A
(zh)
|
2020-08-07 |
2023-07-11 |
福蒂斯治疗公司 |
靶向cd46的免疫偶联物及其使用方法
|
BR112022026577A2
(pt)
|
2020-08-11 |
2023-02-23 |
Kanaph Therapeutics Inc |
Proteína de fusão compreendendo il-12 e anticorpo anti-fap e uso da mesma
|
GB202013477D0
(en)
|
2020-08-27 |
2020-10-14 |
Quell Therapeutics Ltd |
Nucleic acid constructs for expressing polypeptides in cells
|
JP2023539201A
(ja)
|
2020-08-28 |
2023-09-13 |
ジェネンテック, インコーポレイテッド |
宿主細胞タンパク質のCRISPR/Cas9マルチプレックスノックアウト
|
MX2023002330A
(es)
|
2020-09-04 |
2023-03-21 |
Merck Patent Gmbh |
Anticuerpos anti molecula de adhesion celular 5 relacionada con el antigeno carcinoembrionario (ceacam5) y conjugados y usos de los mismos.
|
WO2022076462A1
(en)
|
2020-10-05 |
2022-04-14 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2022087154A1
(en)
|
2020-10-20 |
2022-04-28 |
Repertoire Immune Medicines, Inc. |
Mhc class ii peptide multimers and uses thereof
|
TW202233671A
(zh)
|
2020-10-20 |
2022-09-01 |
美商建南德克公司 |
Peg結合抗mertk抗體及其使用方法
|
WO2022098648A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
CA3196076A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
KR20230095119A
(ko)
|
2020-11-04 |
2023-06-28 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이적 항체를 사용한 치료를 위한 투약
|
IL302412A
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
WO2022159575A1
(en)
|
2021-01-20 |
2022-07-28 |
Bioentre Llc |
Ctla4-binding proteins and methods of treating cancer
|
WO2022161314A1
(zh)
|
2021-01-27 |
2022-08-04 |
信达生物制药(苏州)有限公司 |
针对cd16a的单域抗体及其用途
|
US20240059789A1
(en)
|
2021-01-28 |
2024-02-22 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
JP2024509695A
(ja)
|
2021-02-03 |
2024-03-05 |
ジェネンテック, インコーポレイテッド |
多重特異性結合タンパク質分解プラットフォームおよび使用方法
|
EP4288457A2
(en)
|
2021-02-05 |
2023-12-13 |
Boehringer Ingelheim International GmbH |
Anti-il1rap antibodies
|
WO2022187272A1
(en)
|
2021-03-01 |
2022-09-09 |
Xilio Development, Inc. |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
US20220306743A1
(en)
|
2021-03-01 |
2022-09-29 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
KR20230148226A
(ko)
|
2021-03-10 |
2023-10-24 |
이뮤노웨이크 인크. |
면역조절 분자 및 이의 용도
|
WO2022192647A1
(en)
|
2021-03-12 |
2022-09-15 |
Genentech, Inc. |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
IL305716A
(en)
|
2021-03-16 |
2023-11-01 |
Cytomx Therapeutics Inc |
Activated garaged cytokine constructs and related compositions and methods
|
AU2022241935A1
(en)
|
2021-03-22 |
2023-09-28 |
Novimmune S.A. |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
WO2022200389A1
(en)
|
2021-03-22 |
2022-09-29 |
Novimmune S.A. |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
JP2024511424A
(ja)
|
2021-03-25 |
2024-03-13 |
ダイナミキュア バイオテクノロジー エルエルシー |
抗igfbp7構築物およびその使用
|
EP4319820A1
(en)
|
2021-04-10 |
2024-02-14 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
CA3215965A1
(en)
|
2021-04-19 |
2022-10-27 |
Amy Shen |
Modified mammalian cells
|
CA3216459A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
EP4330282A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
IL307821A
(en)
|
2021-04-30 |
2023-12-01 |
Hoffmann La Roche |
Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody
|
WO2022235940A1
(en)
|
2021-05-06 |
2022-11-10 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against alk and methods of use thereof
|
WO2022236047A1
(en)
|
2021-05-07 |
2022-11-10 |
Viela Bio, Inc. |
Use of an anti-cd19 antibody to treat myasthenia gravis
|
JPWO2022239720A1
(no)
|
2021-05-10 |
2022-11-17 |
|
|
EP4337266A1
(en)
|
2021-05-12 |
2024-03-20 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
EP4341385A1
(en)
|
2021-05-21 |
2024-03-27 |
Genentech, Inc. |
Modified cells for the production of a recombinant product of interest
|
EP4155321A1
(en)
|
2021-06-04 |
2023-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
IL307944A
(en)
|
2021-06-08 |
2023-12-01 |
Xyphos Biosciences Inc |
NKG2D antibody-ligand region fusion protein
|
AU2022291369A1
(en)
|
2021-06-08 |
2023-12-07 |
Xyphos Biosciences Inc. |
Antibody-nkg2d ligand domain fusion protein
|
CN117616123A
(zh)
|
2021-06-25 |
2024-02-27 |
中外制药株式会社 |
抗ctla-4抗体
|
AR126236A1
(es)
|
2021-06-25 |
2023-10-04 |
Chugai Pharmaceutical Co Ltd |
Uso del anticuerpo anti-ctla-4
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
IL309831A
(en)
|
2021-07-13 |
2024-02-01 |
BioNTech SE |
Multispecific binding agents against CD40 and CD137 in combined cancer therapy
|
AU2022317215A1
(en)
|
2021-07-27 |
2024-02-29 |
Astrazeneca Ab |
Treatment of lupus
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
US20230099756A1
(en)
|
2021-08-07 |
2023-03-30 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
WO2023017098A2
(en)
|
2021-08-11 |
2023-02-16 |
King's College London |
Compositions and methods for improved treatment of disorders affecting the central nervous system
|
TW202328177A
(zh)
|
2021-08-27 |
2023-07-16 |
美商建南德克公司 |
治療tau病理學之方法
|
WO2023036982A1
(en)
|
2021-09-10 |
2023-03-16 |
Harbour Antibodies Bv |
Anti-sars2-s antibodies
|
GB202112935D0
(en)
|
2021-09-10 |
2021-10-27 |
Harbour Antibodies Bv |
Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法
|
CA3233663A1
(en)
|
2021-10-08 |
2023-04-13 |
Na CAI |
Activatable cytokine constructs and related compositions and methods
|
WO2023060188A1
(en)
|
2021-10-08 |
2023-04-13 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and combination methods
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
TW202334186A
(zh)
|
2021-10-13 |
2023-09-01 |
美商Cytomx生物製藥公司 |
三聚體的可活化之細胞介素構築體及相關之組成物及方法
|
WO2023079057A1
(en)
|
2021-11-05 |
2023-05-11 |
Sanofi |
Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
|
WO2023081471A1
(en)
|
2021-11-05 |
2023-05-11 |
Dana-Farber Cancer Institute, Inc. |
Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
|
WO2023097024A1
(en)
|
2021-11-24 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against ctla-4 and methods of use thereof
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
TW202340241A
(zh)
|
2021-12-02 |
2023-10-16 |
法商賽諾菲公司 |
Ceacam5 adc-抗pd1/pd-l1組合療法
|
TW202339804A
(zh)
|
2021-12-02 |
2023-10-16 |
法商賽諾菲公司 |
在癌症療法中用於患者選擇的cea測定
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
WO2023114544A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
WO2023114543A2
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
US20230257455A1
(en)
|
2021-12-22 |
2023-08-17 |
Cdr-Life Ag |
Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
|
GB2614309A
(en)
|
2021-12-24 |
2023-07-05 |
Stratosvir Ltd |
Improved vaccinia virus vectors
|
US20230227545A1
(en)
|
2022-01-07 |
2023-07-20 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
WO2023150552A1
(en)
|
2022-02-04 |
2023-08-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treatment of neurological disorders
|
TW202342520A
(zh)
|
2022-02-18 |
2023-11-01 |
美商樂天醫藥生技股份有限公司 |
抗計畫性死亡配體1(pd—l1)抗體分子、編碼多核苷酸及使用方法
|
EP4238988A1
(en)
|
2022-03-01 |
2023-09-06 |
Consejo Superior De Investigaciones Científicas |
Antibodies against sars-cov-2 and uses thereof
|
WO2023172883A1
(en)
|
2022-03-07 |
2023-09-14 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
WO2023172968A1
(en)
|
2022-03-09 |
2023-09-14 |
Merck Patent Gmbh |
Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
|
WO2023170239A1
(en)
|
2022-03-09 |
2023-09-14 |
Merck Patent Gmbh |
Methods and tools for conjugation to antibodies
|
WO2023175171A1
(en)
|
2022-03-18 |
2023-09-21 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Bk polyomavirus antibodies and uses thereof
|
WO2023178357A1
(en)
|
2022-03-18 |
2023-09-21 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
WO2023180353A1
(en)
|
2022-03-23 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023183923A1
(en)
|
2022-03-25 |
2023-09-28 |
Cytomx Therapeutics, Inc. |
Activatable dual-anchored masked molecules and methods of use thereof
|
WO2023192606A2
(en)
|
2022-04-01 |
2023-10-05 |
Cytomx Therapeutics, Inc. |
Cd3-binding proteins and methods of use thereof
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023192973A1
(en)
|
2022-04-01 |
2023-10-05 |
Cytomx Therapeutics, Inc. |
Activatable multispecific molecules and methods of use thereof
|
WO2023201299A1
(en)
|
2022-04-13 |
2023-10-19 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023240287A1
(en)
|
2022-06-10 |
2023-12-14 |
Bioentre Llc |
Combinations of ctla4 binding proteins and methods of treating cancer
|
WO2023245105A1
(en)
|
2022-06-17 |
2023-12-21 |
Genentech, Inc. |
Use of kosmotropes to enhance yield of an affinity chromatography purification step
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024030847A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
WO2024030843A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
WO2024030845A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
WO2024030858A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable substrates and methods of use thereof
|
WO2024030850A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable substrates and methods of use thereof
|
WO2024039670A1
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against cldn4 and methods of use thereof
|
WO2024039672A2
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against msln and methods of use thereof
|
WO2024044779A2
(en)
|
2022-08-26 |
2024-02-29 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024056902A2
(en)
|
2022-09-16 |
2024-03-21 |
Christopher Shaw |
Compositions and methods for treating neurological diseases
|
WO2024079078A1
(en)
|
2022-10-10 |
2024-04-18 |
Uniqure France |
Methods and compositions for treating epilepsy
|